АДГЕЗИВНАЯ КОМПОЗИЦИЯ

Изобретение относится к устройству для стомы, содержащее отверждаемую под воздействием влаги адгезивную композицию. Композиция содержит реакционно-способный компонент, который содержит реакционно-способный силиконовый полимер или смесь реакционно-способных силиконовых полимеров, компонент на основе клейкого материала, который содержит клеящийся при надавливании силиконовый клейкий материал или смесь клеящихся при надавливании силиконовых клейких материалов, представляющий собой поликонденсированную полиорганосилоксановую смолу, которая является продуктом или продуктами реакции полиорганосилоксана с концевыми силанольными группами и силикатной полиорганосилоксановой смолы, содержащей по меньшей мере одно силокси-звено SiO, или силсесквиоксан, имеющий формулу [RSiO], где каждый R отдельно представляет собой H, алкильную группу, арильную группу, реакционно-способную функциональную группу или алкоксигруппу, и n составляет от 4 до 18, в присутствии основания с получением поликонденсированной ...

КОМПОЗИЦИЯ ДЛЯ ВОССТАНОВЛЕНИЯ ТВЕРДЫХ ТКАНЕЙ И НАБОР ДЛЯ ВОССТАНОВЛЕНИЯ ТВЕРДЫХ ТКАНЕЙ

Настоящее изобретение имеет отношение к композиции для восстановления твердых тканей, таких как губчатая кость, и набору для восстановления твердых тканей. Композиция для восстановления твердых тканей содержит 10-45 мас. частей мономера (А), который является мономером на основе (мет)акрилата, 54,9-80 мас. частей полимера (В), который является полимерным порошком на основе (мет)акрилата, 0,1-10 мас. частей инициатора полимеризации (С), который является органическим соединением бора, причем сумма компонентов (А)-(С) принимается равной 100 мас. частей, и 0,5-70 мас. частей контрастного вещества (X), которое является сульфатом бария или цирконием, имеющими средний по объему диаметр частиц 3-25,1 мкм. Набор для восстановления твердых тканей состоит из трех или более элементов, в котором каждый из компонентов вышеуказанной композиции разделены и содержатся в элементах в комбинации по выбору. Технический результат – получение композиции для восстановления твердых тканей и набора для восстановления ...

КЛЕЙ МЕДИЦИНСКИЙ И СПОСОБ ЕГО ПРИГОТОВЛЕНИЯ

Изобретение относится к области медицины, в частности к области хирургических приспособлений, и может быть использовано для склеивания мягких тканей, входящих в состав организма. Клей медицинский содержит 3-метакрилоксисульфолан, N-бутил-2-цианакрилат и, по меньшей мере, один стабилизатор. 2 н. и 5 з.п. ф-лы, 13 пр.

ТРОЙНАЯ СМЕСЬ ДЛЯ КОСТНОГО ЦЕМЕНТА И СПОСОБ ДЛЯ ЕЕ РЕАЛИЗАЦИИ

ПОЛИМЕРЫ, НЕПРОНИЦАЕМЫЕ ДЛЯ РЕНТГЕНОВСКОГО ИЗЛУЧЕНИЯ

ЭМУЛЬСИИ ИЛИ МИКРОЭМУЛЬСИИ ДЛЯ ПРИМЕНЕНИЯ В ЭНДОСКОПИЧЕСКОЙ РЕЗЕКЦИИ СЛИЗИСТОЙ И/ИЛИ ЭНДОСКОПИЧЕСКОЙ ПОДСЛИЗИСТОЙ ДИССЕКЦИИ

УСТРОЙСТВО ДЛЯ СТОМИЧЕСКОГО ИСПОЛЬЗОВАНИЯ

... 1. Устройство для стомического использования, содержащее клеящуюся пластину для крепления к телу, при этом пластина содержит центральное отверстие для размещения стомы, обращенную к коже поверхность и необращенную к коже поверхность, при этом необращенная к коже поверхность оснащена защитным слоем; причем обращенная к коже поверхность пластины содержит1) центральную область, содержащую, по существу, не впитывающий защитный клейкий материал,2) промежуточную область, окружающую центральную область, причем указанная область содержит, по существу, не впитывающий мягкий клейкий материал, и3) крайнюю область, окружающую промежуточную область, при этом указанная крайняя область содержит, по существу, не впитывающий защитный клейкий материал.2. Устройство по п. 1, в котором защитный клейкий материал центральной области и крайней области является одним и тем же.3. Устройство по п. 2, в котором защитный клейкий материал покрывает необращенную к коже поверхность мягкого клейкого материала.4. Устройство ...

УЛУЧШЕННОЕ УПЛОТНЕНИЕ МАНЖЕТЫ ДЛЯ ЭНДОТРАХЕАЛЬНЫХ ТРУБОК

... 1. Гелеобразующий уплотняющий материал для медицинского устройства, причем указанный гелеобразующий уплотняющий материал содержит: ! вязкоупругий материал, проявляющий первую вязкость при введении во внутреннюю полость; и ! вторую вязкость после нахождения во внутренней полости в течение заданного времени, причем указанная полость примыкает к медицинскому устройству, выполненному с возможностью перекрывать по меньшей мере участок указанной внутренней полости; ! при этом указанный вязкоупругий материал обеспечивает повышенную непроницаемость участка указанной внутренней полости, перекрытой медицинским устройством. ! 2. Гелеобразующий уплотняющий материал по п.1, в котором указанное медицинское устройство включает в себя надувную манжету. ! 3. Гелеобразующий уплотняющий материал по п.1, в котором гелеобразующий уплотняющий материал густеет и затем приклеивается к внутренним поверхностям указанной внутренней полости после нахождения во внутренней полости в течение заданного промежутка времени ...

Medizinischer Zement, Verfahren zu seiner Herstellung sowie dessen Verwendung

PARTIKEL FÜR ARZNEISTOFFABGABE

Embolisierende Zubereitungen

Vorrichtung und Verfahren zur Herstellung von Embolisatpartikeln sowie Embolisatpartikeln

Die vorliegende Erfindung betrifft eine Vorrichtung zur Herstellung von Embolisatpartikeln, die eine Mikropipette zur Erzeugung von radikalisch polymerisierbaren Tröpfchen umfasst. Die Tröpfchen münden dabei in einen Zentralkanal, in dem die Tröpfchen von der Ausgangsöffnung der Mikropipette fluidisch weggeführt werden. Dabei wird nach Austritt aus der Austrittsöffnung der Mikropipette bereits eine erste, gegebenenfalls nicht vollständige radikalische Polymerisation der Tröpfchen induziert. Im von der Ausgangsöffnung der Mikropipette wegführenden Zentralkanal findet eine zusätzliche Beschleunigung der Tröpfchen bzw. Partikel statt, wobei verhindert werden kann, dass sich die Tröpfchen gegenseitig beeinflussen. Dadurch kann eine genaue Einstellung der Teilchengrößenverteilung durch Vermeidung von Koaleszenz der Embolisatpartikel erreicht werden. Gegebenenfalls erfolgt abschließend eine weitere Nachpolymerisation der Partikel.

Skin compatible silicone composition

Systems and methods for delivering a polymeric material to a treatment site during a radio frequency ablation procedure

Non-stringy adhesive hydrophilic gels

COMPOSITIONS CONTAINING HIGH CONCENTRATION FROM CONTRAST MEANS TO EMBOLISIERUNG OF BLUTGEFASSEN

MATERIAL AS A CHECK OF ORGANISMS AND FOR THE SELECTIVE ADSORPTION OF PROTEINS, CEMENT AND BIOLOGICAL MATERIAL

COLORCHANGING CYANOACRYLATKLEBER

BONE TRANSPLANT SPARE COMPOSITION

KNOCHENZEMENT ZUR VERANKERUNG VON IMPLANTATEN UND GELENKENDOPROTHESEN

OPTICALLY ABSORBING NANO-PARTICLE FOR THE IMPROVED FABRIC REPAIR

DEVICE FOR CATCHING BODY FLUIDS

DEVICE FOR CATCHING BODY FLUIDS

RAPIDLY EFFECT DRYING SEALING MATERIAL AS WELL AS PROCEDURE FOR THE USE AND PRODUCTION

NEW, SILICONE RUBBER MIXTURE SUITABLE FOR APPLICATION IN THAT ENDOVASCULAEREN AND GENERAL SURGERY AND THIS MIXTURE OF EXHIBITING HEILBEHELF

HIGH-VISCOUS EMBOLISIERENDE MEANS

BONE CEMENT FOR THE ANCHORAGE OF IMPLANTS AND JOINT ENDOPROSTHESES

FABRIC ADHESIVE.

CELLULOSE ACETATE COMPOSITIONS FOR USE WITH THE EMBOLISIERUNG OF BLOOD VESSELS

REINFORCEMENT OF THE ACTIVATION OF BIOLOGICAL FABRIC ADHESIVES, CONNECTION MEANS AND VICTORY-LEARN USING THE CHANGE OF COLOR OF CHROMOPHOREN

SPRAYINGCASH BONE SUBSTITUTE CONTAINING FIBRIN OR FIBRINOGEN AS WELL AS HYDROXYL APATITE CEMENT

DIFERENTIELL BIODEGRADABLE MEDICAL INPLANTATE

ARTICLE WITH STICK-ABLE SURFACE

THREADED SYRINGE WITH QUICK STOP

Functionalized adhesive for medical devices

A method for adhering a medical device to biological tissue includes adhering an adhesive composition having a plurality of reactive members of a specific binding pair to tissue which has a plurality of complementary reactive members of the specific binding pair via click chemistry.

Post irradiation shelf-stable dual paste direct injectable bone cement precursor systems and methods of making same

The present invention relates to a bone cement precursor system that is presented in the form of two shelf-stable pastes which have been terminally sterilized and are held in separate containers during product transport and storage. When the product is used during surgery, these pastes inject to a site of application through a static mixing device by the action of applied injection force. When the two pastes are mixed, they start to react to each other while injecting out. The resulting composition is highly biocompatible, osteoconductive, injectable, rapid setting and bioresorbable, and is useful in connection with bone repair procedures, for example, in the craniomaxillof acial, trauma and orthopedic areas.

METHODS FOR ANEURYSM REPAIR

Methods for aneurysm repair

Radical polymerisation activator for the production of coloured non-toxic organic cements

Polymeric treatment compositions

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological pH solution; wherein the biocompatible polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

Highly efficacious hemostatic adhesive polymer scaffold

The invention relates to biocompatible polymer gel compositions useful in facilitating and maintaining hemostasis. The biocompatible polymeric gel composition is comprised of (a) one or more than one polyanionic polymer, (b) one or more than one polycationic polymer, and (c) a solvent. A preferred composition includes sodium alginate, chitosan, and water to produce an adhesive hemostatic device that is useful in facilitating and maintaining rapid hemostasis.

Compositions and uses of antimicrobial materials with tissue-compatible properties

Compositions comprising a mixture of an antimicrobial cationic polypeptide and a second pharmaceutically-acceptable polymer are disclosed, as well as methods and uses thereof for the treatment and prevention of infections that occur when our natural barriers of defense are broken.

Composition for producing a temporary intestinal occlusion

The present invention relates to the use of a solidifiable composition for producing a temporary occlusion of the intestine of a mammal, wherein the composition is flowable and solidifiable to form a solid plug at a desired location in the intestine. The structure of said plug can be modified for the subsequent, at least partial removal of the occlusion.

Method for improved fibrin sealing

The present invention relates to a fibrin matrix, its preparation and use for effectively sealing a defect in a mucosa or other moist tissue.

BONDING TO CALCIFIED TISSUES

PHOTOACTIVATED CROSSLINKING OF A PROTEIN OR PEPTIDE

A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a crosslinking reaction to form a 3-dimensional matrix of the biomaterial.

KIT AND METHOD FOR PRODUCING BONE CEMENT

The invention provides a kit for producing bone cement. Said kit comprises at least one paste A and one paste B, whereby (a) paste A contains (a1) at least one monomer for radical polymerisation; (a2) at least one polymer that is insoluble in (a1); (a3) at least one polymer that is soluble in (a1); and (a4) at least one radical polymerisation initiator; whereby the weight ratio of the at least one polymer (a2) that is insoluble in (a1) to the at least one polymer (a3) that is soluble in (a1) is at least 2 to 1; and (b) paste B contains (b1) at least one monomer for radical polymerisation; (b2) at least one polymer that is soluble in (b1); and (b3) at least one accelerator that is soluble in (b1), (b4) optionally a polymer (b4) that is insoluble in (b1), whereby the maximal quantity of polymer (b4) that is insoluble in (b1) is 5 % by weight, relative to the total weight of paste B; and whereby the weight ratio of polymer (b4) that is insoluble in (b1) to the at least one poly- mer (b2) that ...

GYNECOLOGIC EMBOLOTHERAPY METHODS

This invention is directed to novel methods for gynecologic embolotherapy. The methods directly access the blood vessels to be embolized transcervically rather than arterially. The methods provide precise directed delivery of embolizing compositions, and are particularly suited for treating uterine fibroids. Kits containing one or more devices for transcervical injection and an embolizing composition are also provided. In a preferred embodiment, fluid embolizing compositions are used. In a more preferred embodiment, these fluid embolic compositions comprise a biocompatible polymer, a biocompatible solvent and a biocompatible water insoluble contrast agent. In a most preferred embodiment, the contrast agent is characterized by having an average particle size of about 10 .mu.m or less.

TISSUE ADHESIVE FOR TREATING VIGOROUSLY BLEEDING SURFACES

... ▓▓▓Disclosed is a novel tissue adhesive technology comprising a combination of ▓ultrasonically treated proteins including collagen and albumin which form a ▓viscous material that develops adhesive properties when chemically cross-▓linked. A novel new cross-linking agent with surprisingly stable properties ▓was developed in association with the tissue adhesive described and claimed ▓herein and is considered to be within the scope of the present invention. This ▓new cross-linking agent is a product of reaction glutaraldehyde with amino ▓acids or peptides and allowing the reacting to proceed to completion. This ▓chemical cross-linking is mixed with the ultrasonically treated proteins, ▓allowed to react for a predetermined time, then used to seal large surface ▓areas of vigorously bleeding tissues including, but not limited to, the liver, ▓lungs and major vascular systems in patients with and without bleeding ▓disorders. This same tissue adhesive has proven to work well in sealing suture ▓sites ...

THERAPEUTIC MICROPARTICLES

Biodegradable, compression resistant microparticles adapted for injection through a catheter system, such as is useful for selective embolization procedures. The microparticles can optimally be neutrally buoyant relative to a target bodily fluid. Various active agents may be included in the microparticles, such an anesthetic which can reduce pain during an embolization procedure. The invention further comprises methods and equipment for testing and delivering compression resistant microparticles.

STABLE, NON-AQUEOUS, SINGLE-PHASE GELS AND FORMULATIONS THEREOF FOR DELIVERY FROM AN IMPLANTABLE DEVICE

The present invention provides a suspension vehicle and suspension formulations deliverable from an implantable delivery device. In particular, the suspension vehicle of the present invention allows the formulation of beneficial agent suspensions that are stable over time at ambient and physiological temperatures. In addition, the beneficial agent suspensions formed using the suspension vehicle of the present invention allow controlled delivery of beneficial agent from an implanted delivery device over sustained periods of time, even when such delivery occurs at low flow rates, through a small-diameter delivery channel. Also included in the present invention are implantable delivery devices.

COMPOSITIONS AND METHODS FOR HEMOSTASIS

COMPOSITIONS COMPRISING OXIDIZED CELLULOSE

The present invention provides compositions comprised of oxidized cellulose (OC) and glycerol, with the ratio of glycerol to OC being at least about 0.5:1 w/w glycerol : OC and/or with the viscosity of the composition being at least 10% higher than that of the glycerol and lower than about 2.6X109 cP, with the total water content being less than about 8% w/w. Further provided is adhesion prevention powder comprised of OC having a carboxyl content of equal to below 18% characterized by high adhesion prevention potency. Uses of the compositions as hemostats or as adhesion prevention material, and methods for the preparation thereof are further provided herein.

COMPOSITIONS AND METHODS FOR VAS-OCCLUSIVE CONTRACEPTION AND REVERSAL THEREOF

Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.

EMULSION COMPRISING PARTICLES

The present invention provides emulsion compositions comprising an continuous oil phase, a discontinuous aqueous phase and a plurality of microparticles. The composition may comprise a pharmaceutical active ingredient located in the oil phase, the particulate phase or the aqueous phase. The emulsion compositions have improved stability and coherence and are useful in the treatment of tumours by embolotherapy.

HIGHLY EFFICACIOUS HEMOSTATIC ADHESIVE POLYMER SCAFFOLD

The invention relates to biocompatible polymer gel compositions useful in facilitating and maintaining hemostasis. The biocompatible polymeric gel composition is comprised of (a) one or more than one polyanionic polymer, (b) one or more than one polycationic polymer, and (c) a solvent. A preferred composition includes sodium alginate, chitosan, and water to produce an adhesive hemostatic device that is useful in facilitating and maintaining rapid hemostasis.

DENTAL CEMENT COMPRISING ASYMMETRIC ACRYLAMIDE-METHACRYLIC ACID ESTER COMPOUND

The present invention provides a dental cement that exhibits excellent adhesiveness to dentin and has high mechanical strength. The present invention relates to a multi-part dental cement containing: an asymmetric acrylamide-methacrylic acid ester compound (a); an acid group-containing (meth)acrylic polymerizable monomer (b); a hydrophobic crosslinkable polymerizable monomer (c); a chemical polymerization initiator (d); and a filler (e). The asymmetric acrylamide-methacrylic acid ester compound (a) is represented by the following general formula (1): (see formula 1) , where X is an optionally substituted, linear or branched C1 to C6 aliphatic group or an optionally substituted aromatic group, the aliphatic group is optionally interrupted by at least one linking group selected from the group consisting of -O-, -S-, -CO-, -CO-O-, -O-CO-, -CO-NR1-, -CO-O-NR1-, -O-CO-NR1-, and -NR1-CO-NR1-, and R1 is a hydrogen atom or an optionally substituted, linear or branched C1 to C6 aliphatic group.

EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION

The invention provides a pharmaceutical composition in form of emulsion or microemulsion for use in an endoscopic procedure, said endoscopic procedure preferably comprising the administration of said pharmaceutical composition to a human. The invention herein disclosed provides a method for performing an endoscopic procedure, said method preferably comprising the administration of a pharmaceutical composition in form of emulsion or microemulsion to a human.

EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION

The invention provides a pharmaceutical composition in form of emulsion or microemulsion for use in an endoscopic procedure, preferably said endoscopic procedure comprising the administration of said pharmaceutical composition to a human with the aim of improving and facilitating the resection of the lesion by raising the area where the lesion is located. The invention herein disclosed provides a method for performing an endoscopic procedure, said method preferably comprising the administration of a pharmaceutical composition in form of emulsion or microemulsion to a human. The invention herein disclosed also provides a kit for use in an endoscopic procedure, said kit comprising a pharmaceutical composition in form of emulsion or microemulsion, an endoscopic injection needle, a syringe and instructions for use thereof.

NANOPARTICLES FOR USE IN BIOADHESION

Use of a composition of nanoparticles for gluing at least one hydrogel to at least one other article. Gel assemblies of good mechanical resistance can be obtained easily. Method for gluing at least one hydrogel to at least one other article, said method comprises: applying a composition of nanoparticles on at least one face of the hydrogel and applying the face of the hydrogel with the nanoparticles to the article.

METHOD FOR THE PRODUCTION OF A POLYMETHYLMETHACRYLATE BONE CEMENT, BONE CEMENT KIT FOR USE IN SAID METHOD, AND BONE CEMENT THAT CAN BE PRODUCED THROUGH SAID METHOD

A subject matter of the invention is a polymethylmethacrylate bone cement. The method comprises the steps of providing a cement powder that contains at least one particulate polymethylmethacrylate or polymethylmethacrylate-copolymer of the sieved fraction of less than 100 µm, one initiator, and at least one particulate or fibrous additive that is insoluble in methylmethacrylate, whereby the additive has an absorption capacity at room temperature of more than or equal to 0.6 g methylmethacrylate per gram of additive; and of providing a monomer solution that contains at least one methylmethacrylate and one activator, and contacting the cement powder and the monomer solution, whereby the mixing takes place without the application of shearing forces. The invention also relates to a bone cement kit for use in said method and bone cement that can be produced through said method.

HYDROGEL FILAMENTS FOR BIOMEDICAL USES

Described herein are apparatus, compositions, systems and associated methods to occlude structures and malformations with radiopaque hydrogel filaments with delayed controlled rates of expansion permitting the repositioning of the device once inside the structure or malformation. Further described is a device for implantation in an animal comprising a difunctional, low molecular weight ethylenically unsaturated shapeable macromer; an ethylenically unsaturated monomer; and a radiopaque element, wherein said device contains no support members. Methods of forming such devices are also disclosed.

BIOLOGICAL THIXOTROPIC ADHESIVE FOR USE IN THE HUMAN BODY INTERNAL CAVITIES

A thixotropic biological adhesive that comprises dextrin and at least one structural component that makes the adhesive thixotropic, and, optionally, at least one antibiotic can be used to stimulate cicatrization of tissue in a patient, for example in order to prevent dehiscence of an anastomosis in the digestive tract of a patient, in order to secure a prosthesis during a hernia operation on a patient and to occlude a fistula in a patient. The thixotropic biological adhesive likewise exhibits an anti-inflammatory effect and can be used with an adipose tissue patch.

COMPOSITIONS AND METHODS FOR TREATING BONE DEFECTS

A bone graft composition includes a biologically-resorbable cement and a plurality of processed bone particles, where each of the bone particles have a shape configured to interconnect with adjacent bone particles. A method for treating a bone defect using the bone graft compositions includes providing the bone graft composition and administering an effective amount of the bone graft composition to a site of a bone defect in a subject. Kits including a biologically-resorbable cement powder and a plurality of processed bone particles are also provided.

MINIMALLY INVASIVE TREATMENT OF VERTEBRA (MITV) USING A CALCIUM PHOSPHATE COMBINATION BONE CEMENT

Featured are a biocompatible, injectable, self-setting, cohesive, bone-bonding and remodeling calcium phosphate composite material and its use in methods of repairing defective bone, e.g., in vertebroplasty augmentation and kyphoplasty.

PASTE-LIKE BONE CEMENT

The present invention relates to a kit comprising a paste A and a paste B, whereby (a) paste A contains (a1) at least one monomer for radical polymerisation; and (a2) at least one barbituric acid derivative as polymerisation initiator; (b) paste B contains (b1) at least one monomer for radical polymerisation; and (b2) at least one heavy metal compound as polymerisation accelerator that is selected from the group consisting of heavy metal salts and heavy metal complexes; and whereby i) paste B contains less than 0.01 % by weight, relative to the total weight of paste B, of a peroxide; ii) at least one of the pastes A and B contains, as component (a3) and/or (b3), at least one filling agent that is poorly soluble or insoluble in (a1) and/or (b1), respectively; and iii) at least one of the pastes A and B contains, as component (a4) and/or (b4), at least one inorganic halide salt. The present invention also relates to the use of the kit for producing a paste for mechanical fixation of articular ...

METHOD FOR IMPROVED FIBRIN SEALING

The present invention relates to a fibrin matrix, its preparation and use for effectively sealing a defect in a mucosa or other moist tissue.

COMPOSITIONS AND METHODS FOR HEMOSTASIS

The present invention relates to water soluble and completely absorbable and/or physiologically degradable hemostatic compositions having a wax or wax-like base effective for use in tamponade hemostasis of bone or cartilage.

LIQUID EMBOLIC COMPOSITIONS AND USES THEREOF FOR TREATING VASCULAR CONDITIONS

The present invention relates generally to polymeric compositions and uses of these compositions to treat vascular conditions. The polymeric composition may comprise a substantially stable biocompatible polymer comprising a reaction product of: a first monomer including a polymerizable moiety having a biodegradable linkage to a visualization agent having at least one aromatic ring, wherein the at least one aromatic ring includes a plurality of iodine atoms, and a second monomer including a polymerizable moiety and at least one hydroxyl group; and a non-physiological solution; wherein the substantially stable biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution. Also described are polymers and embolic systems.

TWO-COMPONENT BONE CEMENT ON ACRYLIC BASIS.

Preparation method of medical adhesive tape

Hydrogel based on linear copolymer, and applications thereof

Clinical medicinal patch with developing coordinates

The invention provides a clinical medicinal patch with developing coordinates. The upper surface of the patch is provided with a developing coordinate identifier, and the developing coordinate identifier is provided with a coordinate mark. The patch is formed by sticking multilayer structures, one or more inner layers are positioned below the path of the top layer, the upper layer of the inner layer is provided with the same coordinate identifier as the developing coordinate identifier of the top layer, and the coordinate identifiers of all layers are superposed. The coordinate identifier of each of the inner layers is also provided with the same coordinate mark as that of the top layer. The developing coordinate identifiers of the top layer and the inner layers are of grids formed by equally spaced transverse lines and longitudinal lines, and also can be multiple rows and multiple columns of equally spaced points. The distances of the grids of the developing coordinate identifiers are ...

ADHESIVE COMPOSITION FOR OSSEOUS FILLING CONTAINING CALCIUM PHOSPHATE TO THE PROPERTIES OF SWELLING.

CONNECTION FOR POCKET OF STOMIE, THE TYPE TWO PARTS, FIXES BY JOINING

L'invention concerne un raccord pour poche de stomie. Elle se rapporte à un raccord pour poche de stomie, du type deux pièces, fixé par collage et comprenant un support muni d'un étrier de fixation à la peau d'un patient et d'une piste de collage, et une poche munie d'une piste de collage portant un adhésif ; l'adhésif de la piste de collage de la poche est une couche d'un adhésif structurel ayant une épaisseur d'au moins 0,6 mm, qui forme une masse adhésive élastomère. L'adhésif de la couche d'adhésif structurel contient un copolymère séquencé à séquences triples, tel qu'un copolymère styrène-isoprène-styrène. La piste de la poche a sa surface portant l'adhésif qui a subi un traitement d'augmentation d'adhérence, tel qu'un traitement d'augmentation de la rugosité. Le raccord peut comporter un organe de positionnement préalable de la piste de la poche par rapport à la piste du support. Application aux poches de colostomie, d'iléostomie et d'urostomie.

EMBOLISATION AGENT

composition, and, the kit

cola cirúrgica, poliéster reticulado preparado a partir da mesma, kit comprendendo a cola cirúrgica e um fotoiniciador, e emplastro

composição para reparo de tecido duro e kit para reparo de tecido duro

Mistura de cimento de ossos e agente de contraste de raios x bem como processo para a sua preparação

New Photoactive Bioadhesive Compositions

Biodegradable lung sealants

The invention relates to a rapid setting liquid lung sealant that forms a highly adherent and elastic hydrogel. Provided are lung sealants comprising two high molecular weight (20 kDa) multi-arm PEG compositions wherein the first PEG composition includes an alkaline buffer and the second PEG composition includes a mildly acidic buffer for optimized set up time and extended working time. In some embodiments, the PEGs further comprise a radioprotectant such as tocopherol. In some embodiments, a colorant is added to one or both PEGs of the lung sealant to improve visualization of the lung sealant against human lung tissue.

ROOT CANAL FILLING MATERIAL

The invention relates to polymerizable compositions which contain polymolecular di(meth)acrylates, curing agents, and additives rendering x-rays opaque, result in cured materials that can be easily removed, and are particularly suitable for filling and sealing root canals.

RAPIDLY ACTING DRY SEALANT AND METHODS FOR USE AND MANUFACTURE

Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.

METHOD OF REMOVING MEDICAL ADHESIVE

Medical adhesive may be removed by applying a solution including tetrahydrofurfuryl acetate (THFA) to the surface upon which is located the adhesive and rubbing the surface to facilitate removal of the adhesive. The solution may be applied to a wipe before application to the surface and the wipe may be used to rub the surface. The surface may be living or dead human or animal skin, hard surfaces and medical instruments. Various additional ingredients may be added to the solution, like perfumes, emollients and other commonly known skin products and polymer diluents.

COLOR CHANGE CYANOACRYLATE ADHESIVES

A cyanoacrylate-based adhesive composition is disclosed. The cyanoacrylate-based adhesive composition includes a cyanoacrylate monomer, and a bleachable dye including a Michler's hydrol cation or derivatized Michler's hydrol cation, paired with a non-nucleophilic anion that provides a stable color to the cyanoacrylate-based adhesive.

METHODS AND DEVICES FOR UTILIZING BONDABLE MATERIALS

The invention primarily relates to fastening and stabilizing tissues, implants, and/or bondable materials, such as the fastening of a tissue and/or implant to a bondable material, the fastening of an implant to tissue, and/or the fastening of an implant to another implant. This may involve using an energy source to bond and/or mechanically to stabilize a tissue, an implant, a bondable material, and/or other biocompatible material. The invention may also relate to the use of an energy source to remove and/or install an implant and/or bondable material or to facilitate solidification and/or polymerization of bondable material.

METHOD AND APPARATUS FOR MAGNETICALLY CONTROLLING CATHETERS IN BODY LUMENS AND CAVITIES

Procédé servant à faire naviguer l'extrémité distale pourvue d'une pointe aimantée d'un dispositif médical allongé à travers le corps et consistant à obtenir une image de la partie du corps à travers laquelle on fait naviguer ce dispositif médical et à utiliser l'image affichée afin d'entrer le trajet souhaité du dispositif médical au moyen de l'identification de points de ce trajet souhaité sur l'image affichée. On détermine le champ magnétique nécessaire pour orienter l'extrémité du dispositif médical dans le sens du trajet souhaité tel que l'indique l'image affichée. Dans un mode de réalisation dans lequel on n'identifie que des points du trajet souhaité, la direction du champ est celle qui est indiquée par ces points. Dans un deuxième mode de réalisation dans lequel on identifie des points du trajet normal et du trajet souhaité, on détermine l'angle de déflexion souhaité et on règle la direction du champ magnétique afin que cet angle atteigne 90°, de manière à être étroitement contigu ...

METHODS AND DEVICES FOR USE WITH SEALANTS

A biocompatible medical sealant for use in a biological system, the sealant comprising a solution of a cross-linkable protein or polypeptide and a solution of a non-toxic cross-linking material which induces cross-linking of said cross-linkable protein, thereby sealing at least a portion of the biological system.

IMPLANT MATERIAL AND A METHOD FOR PRODUCING SAME

The invention relates to an implant material comprising a polymer which is partially cross-linked by means of a metal salt.

Photochemical tissue bonding

Photochemical tissue bonding methods include the application of a photosensitizer to a tissue and/or tissue graft, followed by irradiation with electromagnetic energy to produce a tissue seal. The methods are useful for tissue adhesion, such as in wound closure, tissue grafting, skin grafting, musculoskeletal tissue repair, ligament or tendon repair and corneal repair.

Method of removing medical adhesive

Medical adhesive may be removed by applying a solution including tetrahydrofurfuryl acetate (THFA) to the surface upon which is located the adhesive and rubbing the surface to facilitate removal of the adhesive. The solution may be applied to a wipe before application to the surface and the wipe may be used to rub the surface. The surface may be living or dead human or animal skin, hard surfaces and medical instruments. Various additional ingredients may be added to the solution, like perfumes, emollients and other commonly known skin products and polymer diluents.

ADHESIVE-CONTAINING WOUND CLOSURE DEVICE AND METHOD

A tissue bonding article includes a flexible material, an adhesive substance applied over at least a portion of a bottom side of the flexible material, and a polymerizable adhesive composition permeated throughout at least a portion of the flexible material.

SYNTHETIC TISSUE GLUE

Compositions for use as a tissue glue or sealant are disclosed. The compositions include first and second precursor molecules, wherein the first precursor molecule is a polyoxyethylene-polyoxypropylene block copolymer having at least two nucleophilic groups and the second precursor molecule is a polyoxyethylene-polyoxypropylene block copolymer having at least two electrophilic groups. Biomaterials for use as a tissue glue or sealant, methods of making such biomaterials, devices for applying a biomaterial to a tissue of a patient, methods of sealing a tissue of a patient, and kits also are disclosed.

Antimycotic polymerisable bone cement and a method for the production thereof

The invention describes a bone cement with antimycotic efficacy based on organic polymers, such as polymethylmethacrylate. The bone cement comprises an antimycotic agent, in particular amphotericin B, that is released from the polymerized bone cement in the presence of water or aqueous media, such as body fluids. According to one alternative, the antimycotic agent is present in particulate form and is encapsulated, at least in part, by a mixture of at least one 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid. In addition, a method for the production of a mixture comprising an antimycotic agent, such as amphotericin B particles, and 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid is proposed. Preferably, the antimycotic agent is encapsulated, at least partially, by 1-methylamino-1-deoxy sugar alcohol and at least one fatty acid.

Bone replacement material

A bone replacement material for use in a treatment for repairing a vertebral body compression fracture is formed into a pellet having a roughly polyhedral shape. Each pellet having the roughly polyhedral shape has a pair of opposite surfaces, in which one of the opposite surfaces is inclined with respect to the other surface for a predetermined angle. The angle is preferably in the range of 10 to 60°. Further, the volume of each pellet of the bone replacement material 1 is in the range of 13 to 239 mm3. Furthermore, the bone replacement material is formed of calcium phosphate based compound having the Ca/P ratio of 1.0 to 2.0. By using such a bone replacement material, it is possible to carry out packing operation of the bone replacement material into a collapsed vertebral body smoothly, reliably and safely.

Lung volume reduction using glue compositions

The present invention relates to methods and compositions for sealing localized regions of damaged lung tissue to reduce overall lung volume. The glue compositions provide a glue featuring an adhering moiety coupled to one or more other moieties including, for example, a cross-linkable moiety and/or one other adhering moiety. The methods and compositions of the invention find use, for example, in treating pulmonary conditions, such as emphysema.

Blood coagulation inducing polymer hydrogel

The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated.

Absorbable adhesive paste

An absorbable adhesive paste contains absorbable solid carboxy-bearing microparticles dispersed in a continuous phase of an alkoxyalkyl cyanoacrylate. The paste may contain a soluble absorbable polymeric viscosity modifier and at least one bioactive agent to maximize the effective application as a cover for compromised tissues and wounds or as sealants, blocking agents, or hemostatic agents.

Antimicrobial adhesive system

An adhesive composition having dispersed therein a broad spectrum antimicrobial agent for use in medical applications, such as an adhesive for surgical drapes, wound dressings and tapes, is provided. The adhesive is composed of acrylic polymers, tackifiers and a preferred antimicrobial agent, diiodomethyl-p-tolylsulfone. The subject adhesive composition may be formulated as either an essentially solventless hot melt, or as a solvent based system wherein an emulsion of the antimicrobial agent and the removal of excess solvent is avoided.

Photochemical tissue bonding

Photochemical tissue bonding methods include the application of a photosensitizer to a tissue, e.g., cornea, followed by irradiation with electromagnetic energy to produce a tissue seal. The methods are useful for wound repair, or other tissue repair.

Osteoinductive bone graft injectable cement

Osteoconductive bone graft materials are provided. These compositions contain injectable cements and demineralized bone matrix fibers. The combination of these materials enables the filling of a bone void while balancing strength and resorption.

Composite bone cements with a pmma matrix, containing bioactive antibacterial glasses or glassceramics

A bone cement comprising an acrylic polymeric component and an inorganic component comprising a bioactive glass or glass-ceramic, comprising at least one metal oxide having an anti-bacterial activity, wherein said glass or glass-ceramic component is adapted to release ions of said metal in contact with physiological fluids. The bone cement performs a sustained antibacterial action, also promoting binding with the tissues with which it is contacted, and it is advantageously employed in the fixation of orthopaedic prostheses, in the production of temporary prostheses and in spinal surgery.

Preparation of bone cement compositions

A method for the preparation of injectable ready-to-use paste bone cement compositions by mixing a dry inorganic bone cement powder comprising a particulate calcium sulfate hemihydrate capable of hardening in vivo by hydration of the calcium sulfate hemihydrate forming calcium sulfate dihydrate, an aqueous liquid and an additive that normally retards the setting process, said method comprising a) providing a bone cement powder comprising calcium sulfate hemihydrate, an accelerator for the hardening of the calcium sulfate hemihydrate by hydration, said accelerator being selected from the group consisting of saline and calcium sulfate dihydrate, and a powdered calcium phosphate component b) mixing the bone cement powder with the aqueous liquid for a period of time c) leaving the mixture for the time needed for allowing the hydration reaction of the calcium sulfate hemihydrate to proceed and allowing calcium sulfate dihydrate crystals to form and grow, and d) admixing the additive by means of a short-duration mixing using a minimum of energy surprisingly shortens the setting times for the cement comprising the additive that retard the setting process to the level observed in the absence of the additive and enables a complete hydration of calcium sulfate hemihydrate to calcium sulfate dihydrate, even when using additives else preventing the hardening.

Compositions and methods for arthrodetic procedures

The present invention provides compositions and methods for facilitating fusion of bones in a joint. The present invention provides compositions and methods for promoting fusion of bones in arthrodetic procedures. In one embodiment, a method of performing an arthrodetic procedure comprises providing a composition comprising PDGF disposed in a biocompatible matrix and applying the composition to a site of desired bone fusion in a joint.

Reinforced surgical adhesives and sealants and their in-situ application

In situ application of reinforced adhesive: applying uncured and curable matter to a surface, applying biocompatible inert reinforcing agent comprising at least one curing agent to the uncured composition; allowing curing within subject, cured composition together with the added reinforcing agent being configured to have improved mechanical support and strength.

Kit and method for producing bone cement

A kit for producing bone cement includes at least one paste A and one paste B. Paste A contains at least one monomer (a1) for radical polymerization; at least one polymer (a2) insoluble in monomer (a1); at least one polymer (a3) soluble in monomer (a1); and at least one radical polymerization initiator (a4). The weight ratio of the at least one polymer (a2) to the at least one polymer (a3) is at least 2 to 1. Paste B contains at least one monomer (b1) for radical polymerization; at least one polymer (b2) and at least one accelerator (b3) soluble in monomer (b1); and optionally a polymer (b4) insoluble in monomer (b 1 ). The maximum quantity of polymer (b4) is 5% by weight, relative to the total weight of paste B. The weight ratio of polymer (b4) to the at least one polymer (b2) is no more than 0.2.

FUNCTIONALIZED ADHESIVE FOR MEDICAL DEVICES

A method for adhering a medical device to biological tissue includes adhering an adhesive composition having a plurality of reactive members of a specific binding pair to tissue which has a plurality of complementary reactive members of the specific binding pair via click chemistry. 1. A method for adhering a medical device to biological tissue comprising:providing a bifunctional adhesive composition having a plurality of reactive members of a first specific binding pair and a plurality of reactive members of a second specific binding pair;providing tissue with a plurality of complementary reactive members of the first specific binding pair;contacting the adhesive composition with the biological tissue, wherein upon contact of the reactive members of the first specific binding pair with the complimentary reactive members of the first specific binding pair associated with the tissue, covalent bonds are formed between the reactive members and the complementary reactive members of the first specific binding pair, thus adhering the adhesive to the tissue;providing a medical device having a plurality of complementary reactive members of the second specific binding pair;contacting the medical device with the adhesive, wherein upon contact of the reactive members of the second specific binding pair with the complimentary reactive members of the second specific binding pair associated with the device, covalent bonds are formed between the reactive members and the complementary reactive members of the second specific binding pair, thus adhering the device to the adhesive composition.2. The method for adhering a medical device to biological tissue according to wherein the members of the first specific binding pair bind to one another via a reaction selected from the group consisting of Huisgen cycloaddition reaction claim 1 , a Diels-Alder reaction and a thiol-ene reaction and the members of the second specific binding pair bind to one another via a reaction selected from the ...

Modified starch material of biocompatible hemostasis

A modified starch material for biocompatible hemostasis, biocompatible adhesion prevention, tissue healing promotion, absorbable surgical wound sealing and tissue bonding, when applied as a biocompatible modified starch to the tissue of animals. The modified starch material produces hemostasis, reduces bleeding of the wound, extravasation of blood and tissue exudation, preserves the wound surface or the wound in relative wetness or dryness, inhibits the growth of bacteria and inflammatory response, minimizes tissue inflammation, and relieves patient pain. Any excess modified starch not involved in hemostatic activity is readily dissolved and rinsed away through saline irrigation during operation. After treatment of surgical wounds, combat wounds, trauma and emergency wounds, the modified starch hemostatic material is rapidly absorbed by the body without the complications associated with gauze and bandage removal.

Peg based hydrogel for peripheral nerve injury applications and compositions and method of use of synthetic hydrogel sealants

Hydrogels that may be used for treating peripheral nerves and related methods are provided. Synthetic hydrogel sealants, methods of forming synthetic hydrogel sealants, and the use of synthetic hydrogel sealants are provided.

Thrombin-free biological adhesive and use thereof as a medicament

The invention relates to a thrombin-free, fibrinogen-based biological adhesive for therapeutic use, which comprises factor Vila and a source of calcium ions. The invention also relates to the use of the biological adhesive as a medicament, in particular as a dressing for biological tissues, wounds or biomaterials.

Adhesive complex coacervates and method of making and using thereof

Described herein is the synthesis of adhesive complex coacervates and their use thereof. The adhesive complex coacervates are composed of a mixture of one or more polycations and one or more polyanions. The polycations and polyanions in the adhesive complex coacervate are crosslinked with one another by covalent bonds upon curing. The adhesive complex coacervates have several desirable features when compared to conventional bioadhesives, which are effective in water-based applications. The adhesive complex coacervates described herein exhibit good interfacial tension in water when applied to a substrate (i.e., they spread over the interface rather than being beaded up). Additionally, the ability of the complex coacervate to crosslink intermolecularly increases the cohesive strength of the adhesive complex coacervate. They have numerous biological applications as bioadhesives and drug delivery devices and are particularly useful in underwater applications and situations where water is present such as, for example, physiological conditions.

Light Activated Composite Tissue Adhesives

A light activated collagen-flavin composite layer incorporating riboflavin is applied as treatment for infected lesions caused by bacteria and as the consequence of surgical procedures. These composites have also been found to be strong tissue adhesives that are effective in closing and sealing wounds, fixation of grafts/ implants and anastomoses. Advantages include speed of closure, reduced infection due to the elimination of foreign matter, evidence of accelerated wound healing and the ease of use in complex surgery, especially when watertight seals, limited access or small repair size are important factors. The riboflavin in the collagen layer is exposed to light (e.g., light having a wavelength between 360-375 nm or 440-480 nm), decomposing the riboflavin to form reactive oxygen species (ROS). Strong crosslinks between the collagen composite and tissue results. In addition, similar exposures eradicate pathogens in the wound is eradicated resulting in a sterile wound. In other examples, the composite film may instead contain lumichrome or lumiflavin. 1. A composition , comprising:gelatin, wherein a concentration of the gelatin in the composition is in a range of 20% (w/v) to 50% (w/v);collagen, wherein a concentration of the collagen in the composition is in a range of 10% to 40% (w/v); anda chromophore that produces a reactive oxygen species upon exposure to electromagnetic radiation.2. A composition in accordance with claim 1 , wherein the chromophore includes riboflavin.3. A composition in accordance with claim 1 , wherein a concentration of the riboflavin in the composition is within a range of 0.1% to 2.0% (w/v).4. A composition in accordance with claim 1 , wherein the concentration of the riboflavin in the composition is substantially equal to 1.0%.51. A composition in accordance claim 1 , wherein the chromophore includes lumiflavin.6. A composition in accordance with claim 1 , wherein the chromophore includes lumichrome.7. A composition in accordance with ...

Temporary Embolization Using Inverse Thermosensitive Polymers

One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound.

Apatite Forming Biomaterial

The present invention relates to chemically bonded ceramic biomaterials, especially a dental material or an implant material. The main binder system forms a chemically bonded ceramic upon hydration thereof, and comprises powdered calcium aluminate and/or calcium silicate, and phase(s) to secure apatite formation at a pH close to neutrality. A second binder system—a cross-linking organic binder system which provides for initial crosslinking of the freshly mixed paste is advantageously added. The invention relates to a powdered composition for preparing the inventive chemically bonded ceramic biomaterial, and a paste from which the biomaterial is formed, as well as a kit comprising the powdered composition and hydration liquid, as well as methods and use of the biomaterial in dental and implant applications with the aim of remineralisation, integration and bone repair.

High Adhesion Antimicrobial Skin Prep Solution and Related Methods

Antimicrobial skin prep solutions of the invention comprise: a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent; an antimicrobially effective amount of at least one antimicrobial agent; and an amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution, wherein the at least one adhesive is distinct from the at least one antimicrobial agent and is a liquid at room temperature. Coated substrates, applicators, and related methods are also disclosed. 1. An antimicrobial skin prep solution comprising:a major amount of at least one organic solvent, wherein at least about 80% by weight based on total weight of the solvent comprises at least one fugitive organic solvent;an antimicrobially effective amount of at least one antimicrobial agent; andan amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution,wherein the at least one adhesive is distinct from the at least one antimicrobial agent and is a liquid at room temperature.2. The antimicrobial skin prep solution of claim 1 , wherein the amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution is about 2% by weight of the skin prep solution.3. The antimicrobial skin prep solution of claim 1 , wherein the amount of at least one adhesive effective to increase adhesion of surgical drapes and medical dressings to skin prepped with the antimicrobial skin prep solution is about 5.5% by weight of the skin prep solution.4. The antimicrobial skin prep solution of claim 1 , wherein the at least one adhesive is a hydrogel in the skin prep solution.5. The antimicrobial skin prep solution of claim 1 , wherein the ...

Methods of building a body portion

An improved method of implanting cells in the body of a patient includes positioning viable cells on a support structure. One or more blood vessels may be connected with the support structure to provide a flow of blood through the support structure. A support structure may be positioned at any desired location in a patient's body. The support structure may be configured to replace an entire organ or a portion of an organ. An organ or portion of an organ may be removed from a body cells and/or other tissue is removed to leave a collagen matrix support structure having a configuration corresponding to the configuration of the organ or portion of an organ. Alternatively, a synthetic support structure may be formed. The synthetic support structure may have a configuration corresponding to a configuration of an entire organ or only a portion of an organ.

BIOLOGIC BONDING AGENT

A sterile biofilm could be engineered to isolate the glue-like substance while eliminating the adverse properties of the bacteria. The resulting sterile glue-like substance would be used to help the cells stick to the support structure. The engineered biofilm could be added to the support structure in the laboratory that produces the support structure or just prior to the addition of the cells by the user. Alternatively, the biofilm and support structure could be combined intra-corporally. This biofilm also could be used as an independent polysaccharide based adhesive with mild to moderate adhesion forces. The biofilm could serve as a surgical adhesion or grouting for cells, for tissue fixation (soft tissue to soft tissue, soft tissue to bone, etc.) and as a sealant. The biofilm could be used in conjunction with other implants and devices. The biofilm could be used to coat a stent. 1. A biologic bonding agent comprising:an engineered adhesive derived at least in part from a bacterial source; andthe adhesive being configured to be collected, processed to be substantially free of viable bacteria, and placed in a container,wherein adhesive properties of the bacterial source are substantially maintained.2. The bonding agent of claim 1 , wherein the bacterial source includes biofilm.3. The bonding agent of claim 1 , wherein at least a portion of the adhesive is polysaccharide based.4. The bonding agent of claim 1 , wherein the adhesive is configured to be coated on or impregnated in at least a portion of an implant.5. The bonding agent of claim 1 , wherein at least a portion of the adhesive is biodegradable.6. The bonding agent of claim 1 , wherein the adhesive is configured to be coated on or impregnated in at least a portion of a stent.7. The bonding agent of claim 1 , wherein the adhesive is configured to be applied to at least a portion of a collagen material.8. The bonding agent of claim 1 , wherein the adhesive is configured to promote attachment of cells to a ...

MEDICAL ADHESIVE FILM

An adhesive film including an upper surface including a developing reference axis. The adhesive film is simple in structure, accurate in positioning, and convenient for practice. 12. An adhesive film , comprising an upper surface comprising a developing reference axis ().223. The adhesive film of claim 1 , wherein the developing reference axis () is provided with reference numbers ().3. The adhesive film of claim 2 , wherein{'b': 1', '1, 'i': a,', 'b, 'the adhesive film comprises an uppermost adhesive film and a plurality of layers of inner adhesive films (. . . );'}{'b': 1', '1, 'i': a,', 'b, 'the inner adhesive films (. . . ) are disposed beneath the uppermost adhesive film;'}{'b': 2', '2', '2, 'i': a,', 'b, 'each of the inner adhesive films comprises an upper surface comprising a reference axis (. . . ) being the same as the developing reference axis () arranged on the uppermost adhesive film; and'}{'b': 2', '2, 'i': a,', 'b, 'the reference axis (. . . ) arranged on each of the inner adhesive films superposes with one another.'}4221133a,ba,ba,b. The adhesive film of claim 3 , wherein the reference axis (. . . ) arranged on each inner adhesive film (. . . ) is provided with reference numbers (. . . ).52. The adhesive film of claim 1 , wherein the developing reference axis () is in a grid structure formed by arranging transverse lines and vertical lines at equal intervalss between each other.622a,b. The adhesive film of claim 3 , wherein the reference axis (. . . ) arranged on each inner adhesive film is in a grid structure formed by arranging transverse lines and vertical lines at equal intervals between each other.722a,b. The adhesive film of claim 4 , wherein the reference axis (. . . ) arranged on each inner adhesive film is in a grid structure formed by arranging transverse lines and vertical lines at equal intervals between each other.82. The adhesive film of claim 5 , wherein vertical lines and/ or transverse lines of the developing reference axis () ...

COMPOSITION CONTAINING INJECTABLE SELF-HARDENED APATITE CEMENT

A method of producing an injectable calcium phosphate paste by a process in which calcium phosphate precursors are mixed with the setting fluids to form a self-hardened apatite cement is disclosed. The produced apatite cement is biocompatible, bioactive and biodegradable in the body. The pH value of said apatite cement is approximately 7 with compressive strength between 10-30 MPa and the setting process will not generate.temperature >37° C. The self-hardened apatite (SHA) cement is found to be bioresorbable and can be used for bone fillers, fixation of broken bones or artificial joints in human and also appropriate for use as a delivery vehicle. 1. A composition of injectable self-hardened apatite cement comprising:{'sub': 3', '4', '2', '4', '4', '2, 'a. a main matrix comprising tri-calcium phosphate (TCP; Ca(PO)) and tetra-calcium phosphate (TTCP; Ca(PO)O),'}{'sub': 2', '3', '6', '8', '7', '6', '5', '3', '7', '2, 'b. hardening agents comprising sodium carbonate (NaCO), citric acid, (CHO) and sodium citrate (CHNaO.2HO),'}c. setting fluids andd. filler and pH stabiliser.2. The composition according to wherein the filler and pH stabiliser is hydroxyapatite (Ca(PO)(OH)).3. The composition according to claim 1 , wherein the weight ratio of tri-calcium phosphate to tetra-calcium phosphate is in the range of 45:55 to 55:45.4. The composition according to claim 1 , wherein said sodium carbonate is present in an amount ranging from about 5 to 10 weight percentage.5. The composition according to claim 1 , wherein said citric acid is present in an amount ranging from about 20 to 30 weight percentage.6. The composition according to claim 1 , wherein said sodium citrate is present in an amount ranging from about 5 to 10 weight percentage.7. The composition according to claim 1 , wherein said filler and/or pH stabiliser is present in an amount ranging from about 1 to 5 weight percentage.8. The composition according to claim 1 , wherein the setting fluids are selected from a ...

TISSUE ADHESIVE BASED ON NITROGEN-MODIFIED ASPARTATES

The invention relates to a polyurea system comprising as component A) isocyanate-functional prepolymers which can be obtained by reacting aliphatic isocyanates A1) with polyols A2) that can have a number-average molecular weight of =400 g/mol and an average OH functionality of 2 to 6 in particular; and as component B) amino-functional aspartic acid esters of the general formula (I) in which X is an organic group containing a secondary amino function, R1, R2 are the same or different organic groups that do not have Zerewitinoff-active hydrogen, and n is a whole number of at least 2, in particular for sealing, bonding, gluing, or covering cell tissue. The invention also relates to a metering system for the polyurea system according to the invention. 115-. (canceled)18. The polyurea system as claimed in claim 17 , wherein Rand Rin each case independently of one another or simultaneously are a linear or branched saturated organic radical optionally also substituted in the chain with heteroatoms.19. The polyurea system as claimed in claim 16 , wherein the radicals Rand Rin each case independently of one another are linear or branched C1 to C10 organic radicals.20. The polyurea system as claimed in claim 17 , wherein Rand Rin each case independently of one another or simultaneously are a linear or branched claim 17 , saturated claim 17 , aliphatic C2 to C6 claim 17 , and the radicals Rand Rin each case independently of one another are linear or branched C2 to C4 aliphatic hydrocarbon radicals.21. The polyurea system as claimed in claim 16 , wherein the polyols A2) contain polyesterpolyols and/or polyester-polyether-polyols and/or polyetherpolyols with an ethylene oxide fraction between 60 and 90% by weight.22. The polyurea system as claimed in claim 16 , wherein the polyols A2) contain polyester-polyether-polyols and/or polyetherpolyols with an ethylene oxide fraction between 60 and 90% by weight.23. The polyurea system as claimed in claim 16 , wherein the polyols A2) ...

Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels

Pharmaceutically acceptable hydrogel polymers of natural, recombinant or synthetic origin, or hybrids thereof, are introduced in a dry, less hydrated, or substantially deswollen state and rehydrate in a physiological environment to undergo a volumetric expansion and to affect sealing, plugging, or augmentation of tissue, defects in tissue, or of organs. The hydrogel polymers may deliver therapeutic entities by controlled release at the site. Methods to form useful devices from such polymers, and to implant the devices are provided.

TISSUE ADHESIVE WITH ACCELERATED CURING

The present invention relates to a polyurea system encompassing as component A) isocyanate-functional prepolymers obtainable by reaction of aliphatic isocyanates A1) with polyols A2), which can in particular have a number average molecular weight of ≧400 g/mol and an average OH functionality of 2 to 6, as component B) amino-functional compounds of general formula (I) in which X is an organic residue comprising a tertiary amino function, having no Zerewitinoff active hydrogen, Ris a CH—COORresidue, in which Ris an organic residue having no Zerewitinoff active hydrogen, a linear or branched C1 to C4 alkyl residue, a cyclopentyl or cyclohexyl residue or H, Ris an organic residue having no Zerewitinoff active hydrogen, n is an integer ≧2 or ≦3, in particular for closing, binding, bonding or covering cell tissue, and to a metering system for the polyurea system according to the invention. 114-. (canceled)17. The polyurea system according to claim 16 , wherein R claim 16 , R claim 16 , Rare claim 16 , each independently of one another or simultaneously claim 16 , a linear or branched claim 16 , saturated organic residue that is optionally also substituted in the chain with heteroatoms claim 16 , in particular a linear or branched claim 16 , saturated claim 16 , aliphatic C1 to C10 claim 16 , preferably C2 to C8 and particularly preferably C2 to C6 hydrocarbon residue.18. The polyurea system according to claim 17 , wherein R claim 17 , R claim 17 , Rare claim 17 , each independently of one another or simultaneously claim 17 , a methyl claim 17 , ethyl claim 17 , propyl or butyl residue claim 17 , wherein at least one of R claim 17 , R claim 17 , Ris a methylene claim 17 , ethylene claim 17 , propylene or butylene residue.19. The polyurea system according to wherein R claim 15 , Rand optionally Rare claim 15 , each independently of one another or simultaneously claim 15 , a linear or branched C1 to C10 claim 15 , preferably C1 to C8 claim 15 , particularly preferably C2 to ...

BIORESORBABLE EMBOLIZATION MICROSPHERES

The present disclosure is generally directed to an embolic material which, in some embodiments, may be in the form of a microsphere or a plurality of microspheres. The embolic material generally comprises carboxymethyl chitosan (CCN) crosslinked with carboxymethyl cellulose (CMC). In some embodiments, the embolic material may further comprise a therapeutic agent, such as doxorubicin. 1. An embolic material comprising at least one microsphere comprising carboxymethyl chitosan crosslinked with carboxymethyl cellulose.2. The embolic material of claim 1 , wherein the microsphere comprises a diameter between about 100 micrometers and about 1200 micrometers.3. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 300 micrometers and about 500 micrometers.4. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 100 micrometers and about 300 micrometers.5. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 700 micrometers and about 900 micrometers.6. The embolic material of claim 1 , wherein the microsphere comprises a diameter of between about 900 micrometers and about 1200 micrometers.7. The embolic material of claim 1 , wherein the microsphere further comprises a therapeutic agent.8. The embolic material of claim 7 , wherein the therapeutic agent comprises a chemotherapeutic agent.9. The embolic material of claim 7 , wherein the therapeutic agent comprises at least one positively charged functional group.10. The embolic material of claim 7 , wherein the therapeutic agent comprises at least one of irinotecan claim 7 , ambroxol claim 7 , or doxorubicin.11. The embolic material of claim 7 , wherein a concentration of the therapeutic agent is between about 0.3 milligram of therapeutic agent per milligram of dry microsphere and about 0.75 milligram of therapeutic agent per milligram of dry microsphere.12. The embolic material of claim 1 , wherein ...

Bioadhesive for Soft Tissue Repair

The present invention provides compositions and methods for repair and reconstruction of defects and injuries to soft tissues. Some aspects of the invention provide tissue adhesives comprising a hybrid hydrogel by using a naturally derived polymer, gelatin and a synthetic polymer, polyethylene glycol, wherein the hydrogel is biocompatible, biodegradable, transparent, strongly adhesive to corneal tissue, and have a smooth surface and biomechanical properties similar to the cornea.

ONE COMPONENT FIBRIN GLUE COMPRISING A POLYMERIZATION INHIBITOR

Provided herein are stable liquid sealant formulations comprising fibrin monomers and a reversible fibrin polymerization blocking agent, methods of preparing and using the formulations. 113-. (canceled)14. A method for preparing a sealant at a surface comprising: providing a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 , 21 , 22 , 23 , 24 , and 25° C.; and applying the formulation to the surface under conditions which facilitate fibrin polymerization at the surface.15. The method of claim 14 , wherein the conditions comprise removing claim 14 , blocking claim 14 , neutralizing and/or diluting the GPRP peptide.1620-. (canceled)21. A method of healing claim 14 , sealing and/or reducing blood loss in a subject in need claim 14 , comprising applying to the subject an effective amount of a liquid sealant formulation comprising fibrin monomers at a concentration of 1 to 13% (w/v) and a GPRP peptide for reversible blocking fibrin polymerization wherein the GPRP peptide is present in the formulation in an amount which is greater than 100-fold molar excess relative to the fibrin monomers; and wherein the liquid formulation is stable for at least 14 days at an ambient temperature selected from the group consisting of about 20 claim 14 , 21 claim 14 , 22 claim 14 , 23 claim 14 , 24 claim 14 , and 25° C.22. (canceled) The instant application contains a Sequence Listing, which is submitted concomitantly with this application via EFS-Web in ASCII format and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Dec. 22, 2013, is named “sequencelisting” and is 8 ...

HYDROGELS AND USE THEREOF IN ANASTOMOSIS PROCEDURES

This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic β-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures. 1. A peptide hydrogel comprising a fibrillar network of peptides , wherein:the hydrogel undergoes a gel-sol phase transition upon application of shear stress, and a sol-gel phase transition upon removal of the shear stress; andthe peptides are in an amphiphilic β-hairpin conformation and comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel.2. The peptide hydrogel of claim 1 , wherein:the amphiphilic β-hairpin conformation comprises a β-turn, a first β-strand, a second β-strand, a hydrophobic face, and a hydrophilic face;the assembly of the peptides in the fibrillar network comprises hydrophobic interactions between the hydrophobic faces of the peptides;the first β-strand comprises the photocaged glutamate residue, the second β-strand comprises a glycine residue, and the sidechains of the photocaged glutamate residue and the glycine residue are proximal to each other on the hydrophobic faces of the peptides; anduncaging the photocaged glutamate residues disrupts the hydrophobic interactions between the peptides by exposing negative charges of the glutamate residues, thereby disrupting the fibrillar network and triggering the irreversible gel-sol phase transition ...

EMULSIONS OR MICROEMULSIONS FOR USE IN ENDOSCOPIC MUCOSAL RESECTIONING AND/OR ENDOSCOPIC SUBMUCOSAL DISSECTION

The present invention relates to a pharmaceutical composition in form of emulsion or microemulsion and the use thereof as aid during endoscopic procedures in which it is injected in a target tissue in order to form a cushion. More in details, the invention relates to a method for performing an endoscopic procedure, which comprises injecting said pharmaceutical composition in form of emulsion or microemulsion in a target tissue of a patient, in order to form a cushion, which cushion is then optionally subjected to an endoscopic surgical procedure, such as a resection. 1. A kit comprising a pharmaceutical composition in a container , wherein the pharmaceutical composition comprises:(a) at least one poloxamer selected from poloxamer 124, poloxamer 188, poloxamer 237, poloxamer 338, and poloxamer 407, or a mixture thereof; and(b) means for keeping the pharmaceutical composition in liquid phase up to a temperature of about 40° C. in vitro.2. The kit according to claim 1 , wherein the container is selected from an ampoule claim 1 , a vial claim 1 , a bottle claim 1 , and a pre-filled syringe.3. The kit according to claim 2 , wherein the container is an ampoule.4. The kit according to claim 3 , wherein the ampoule contains from 10 mL to 50 mL of the pharmaceutical composition.5. The kit according to claim 2 , wherein the container is a vial.6. The kit according to claim 5 , wherein the vial contains from 10 mL to 50 mL of the pharmaceutical composition.7. The kit according to claim 2 , wherein the container is a bottle.8. The kit according to claim 2 , wherein the container is a pre-filled syringe.9. The kit according to claim 8 , wherein the pre-filled syringe contains from 5 mL to 10 mL of the pharmaceutical composition.10. A method for creating a cushion in a submucosal tissue in the gastrointestinal tract of a patient claim 8 , comprising injecting into the submucosal tissue a pharmaceutical composition comprising:(a) at least one poloxamer selected from poloxamer 124, ...

A conductive elastomer, preparation method and use thereof

A preparation method of a conductive elastomer includes the following steps: (1) according to the mass percent of 20˜75%, dissolving the metallic salts into deionized water to form an electrolyte solution, wherein said metallic salts is either of magnesium nitrate, sodium nitrate, zinc nitrate, cesium nitrate, calcium nitrate, neodymium nitrate, aluminum nitrate, potassium nitrate, potassium chloride, magnesium chloride, calcium chloride, sodium chloride, zinc chloride, cesium chloride, aluminum chloride or their combinations; (2) according to the mass percent of 10˜40%, mixing starches into the electrolyte solution prepared in step (1), then at the temperature of 33˜120 ° C., stirring to gelatinize the starches, forming a viscous liquid; (3) standing the viscous liquid obtained in step (2) at 25˜90° C. for 10 min to 48 h to obtain the conductive elastomer.

Electrically conductive adhesive

One aspect refers to an electrically conductive adhesive including a) a (meth)acrylate monomer, b) a polymer being soluble in the (meth)acrylate monomer, c) a biocompatible metal having a median particle size d50 of below 50 μm, and d) a polymerization initiator. One aspect also refers to a kit for preparing an electrically conductive adhesive, to an implantable medical device including such an electrically conductive adhesive, or a cured form thereof, and to the use of such an electrically conductive adhesive.

IMPLANTATION DEVICES INCLUDING HYDROGEL FILAMENTS

Described are devices for implantation comprising a hydrogel filament wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer, an ethylenically unsaturated monomer, and a visualization agent. Methods of making and using these devices are also described. 1. A device for implantation comprising:a hydrogel filament attached to a coupler wherein the coupler is attached to a pusher,wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer; an ethylenically unsaturated monomer; and a visualization agent,wherein said device contains no support members.2. The device of claim 1 , wherein said macromer has a molecular weight of about 100 grams/mole to about 5000 grams/mole.3. The device of claim 1 , wherein said macromer comprises polyethylene glycol claim 1 , propylene glycol claim 1 , poly(tetramethylene oxide) claim 1 , poly(ethylene glycol) diacrylamide claim 1 , poly(ethylene glycol) diacrylate claim 1 , poly(ethylene glycol) dimethacrylate claim 1 , derivatives thereof claim 1 , or combinations thereof.4. The device of claim 1 , wherein said visualization agent comprises an aromatic ring having a single unsaturation point and at least one iodine atom.5. The device of claim 1 , wherein said visualization agent comprises barium sulfate claim 1 , gadolinium claim 1 , or iron oxide.6. The device of claim 5 , wherein said visualization agent is barium sulfate.7. The device of claim 1 , wherein said ethylenically unsaturated monomer and said visualization agent comprise 2 claim 1 ,4 claim 1 ,6-triiodophenyl penta-4-enoate claim 1 , 5-acrylamido-2 claim 1 ,4 claim 1 ,6-triiodo-n claim 1 ,n′-bis-(2 claim 1 ,3 dihydroxypropyl) isophthalamide claim 1 , derivatives thereof claim 1 , or combinations thereof.8. The device of claim 1 , wherein said macromer and said monomer are crosslinked with N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetramethylethylenediamine claim 1 , ammonium persulfate claim 1 , ...

Adhesive Composition

The present invention relates to an adhesive composition applicable to skin comprising: (i) a polar oil or fat including (a) at least one triglyceride and/or (b) at least one fatty acid of the formula R—COH, wherein R is a Cto Calkyl group; and (ii) at least one homopolymer, and/or copolymer. This invention also relates to a medical adhesive device including such adhesive composition. 2. (canceled)3. (canceled)4. (canceled)5. The adhesive composition of further comprising at least one tackifier.6. The adhesive composition of claim 5 , wherein the tackifier is selected from the group consisting of natural rosin claim 5 , modified rosin claim 5 , glycerol ester of natural rosin claim 5 , glycerol ester of modified rosin claim 5 , pentaerythritol ester of natural rosin claim 5 , pentaerythritol ester of modified rosin claim 5 , phenolic-modified terpene resin claim 5 , aliphatic petroleum hydrocarbon resin claim 5 , and cycloaliphatic resin.7. (canceled)8. (canceled)9. The adhesive composition of claim 1 , wherein the base polymer comprises at least two immiscible monomers.10. The adhesive composition of further comprising a hydrophilic fluid-absorbing gum or gel-thickener claim 1 , wherein the gum or gel-thickener is cationic claim 1 , anionic claim 1 , or non-ionic.11. The adhesive composition of claim 10 , wherein the gel-thickener is a water soluble or swellable hydrocolloid or a mixture thereof.12. The adhesive composition of claim 11 , wherein the gel-thickener is selected from a group consisting of carboxymethylcellulose claim 11 , hydroxyethylcellulose (HEC) claim 11 , hydroxypropylcellulose (HPC) claim 11 , pectin claim 11 , carrageenan claim 11 , and gelatin.13. A medical adhesive device comprising an adhesive composition comprising coconut oil claim 11 , a mineral oil claim 11 , and a base polymer.14. The adhesive device of claim 13 , wherein the adhesive composition further comprises a tackifier.15. The adhesive device of claim 14 , wherein the tackifier is ...

OSTOMY DEVICE

Disclosed is an ostomy device with an adhesive wafer for attachment to a skin surface of a user and a collecting bag for collecting output from a stoma. The collecting bag is connected to the adhesive wafer, and the adhesive wafer has a through-going hole for accommodating the stoma of the user. The adhesive wafer includes a backing layer, a first switchable adhesive composition (), a second absorbent adhesive composition (), and a release liner. 125-. (canceled)26. An ostomy device comprising an adhesive wafer for attachment to a skin surface of a user , and a collecting bag connected to the adhesive wafer; the adhesive wafer having a through-going hole for accommodating the stoma of the user; and the adhesive wafer comprising a backing layer , a first switchable adhesive composition , a second absorbent adhesive composition , and a release liner , wherein the adhesive wafer has a central part adjacent to the hole for accommodating the stoma and a peripheral part adjacent to an edge of the adhesive wafer away from the hole , and wherein the second absorbent adhesive composition is located at least in the central part of the adhesive wafer , wherein the release liner is in contact with the first switchable adhesive composition in the peripheral part of the adhesive wafer , and wherein the release liner is in contact with the second absorbent adhesive composition in the central part of the adhesive wafer.27. The ostomy device according to claim 26 , wherein the switchable adhesive composition is switchable from a high-tack state with a first peel force to a lower-tack state with a second peel force.28. The ostomy device according to claim 27 , wherein the first peel force is higher than the second peel force.29. The ostomy device according to claim 27 , wherein the peel force is measured by a 90 degree peel test.30. The ostomy device according to claim 27 , wherein a reduction in peel force between the first peel force and the second peel force is at least 50%.31. ...

METHOD AND APPARATUS FOR DERMATOLOGICAL TREATMENT

Exemplary methods and systems can be provided for resurfacing of skin that include formation of a plurality of small holes, e.g., having widths greater than about 0.2 mm and less than about 0.7 mm or 0.5 mm, using a mechanical apparatus. Compressive and/or tensile forces can then be applied to the treated region of skin as the damage heals to facilitate hole closure, and provide enhanced and/or directional shrinkage of the treated skin area. 1. A cosmetic method for producing an effect in skin , tissue , comprising:forming a plurality of holes in a region of the skin tissue using at least one coring needle; andproviding a stress that is at least one of a compressive stress or a tensile stress in the region of skin tissue after forming the holes,wherein a diameter of the holes is between 0.2 mm and 0.7 mm,wherein the holes extend from the skin surface into the dermal layer of the skin, wherein the holes extend over an areal fraction of a surface of the region that is between 5% and 50%,wherein the stress provides a force in the region, along a direction that is parallel, to the surface of the region, andwherein the stress is maintained on the surface of the region until the holes have closed.2. The method of claim 1 , wherein a diameter of the holes is between 0.2 mm and 0.5 mm.3. The method of claim 1 , wherein the holes ex tend over the areal fraction of the surface of the region that is between 10% and 30%.4. The method of claim 1 , wherein the holes extend through an. entire depth of the dermal layer.5. The method of claim 1 , wherein the stress is the compressive stress which is provided by adhering a pre-stretched film over at least one portion of the region claim 1 ,6. The method of claim 5 , further comprising adhering a rigid object onto the pre-stretched. film after the pre-stretched film has been adhered to the at least one portion of the region.7. The method of claim 6 , wherein the rigid object is at least one of a rigid film or a plate.8. The method of ...

Temporary Embolization Using Inverse Thermosensitive Polymers

One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound. 1. A method of temporarily embolizing a vascular site in a mammal , comprising the step of:introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, thereby temporarily embolizing a vascular site of said mammal.2. The method of claim 1 , wherein said mammal is a human.3. The method of claim 1 , wherein the transition temperature of said inverse thermosensitive polymer is between about 10 C and about 40 C.4. The method of claim 1 , wherein the volume of the inverse thermosensitive polymer between its transition temperature and physiological temperature is between about 80% and about 150% of the volume of the inverse thermosensitive polymer below its transition temperature.5. The method of claim 1 , wherein said inverse thermosensitive polymer is a block copolymer claim 1 , random copolymer claim 1 , graft polymer claim 1 , or branched copolymer.6. The method of claim 1 , wherein said inverse thermosensitive polymer is a block copolymer.7. The method of claim 1 , wherein said inverse thermosensitive polymer is a polyoxyalkylene block copolymer.8. The method of claim 1 , wherein said inverse thermosensitive polymer is a poloxamer or poloxamine.9. The method of claim 1 , wherein said inverse thermosensitive polymer is a poloxamer.10. The method of claim 1 , wherein said inverse thermosensitive ...

ANTI-ADHESION POLYMER COMPOSITION CAPABLE OF SUPPORTING GROWTH FACTOR

The present invention relates to an anti-adhesion polymer composition capable of supporting growth factor, which effectively exhibits anti-adhesion function and, at the same time, has an excellent adhesive property so as to be able to easily and continuously adhere to a wound site, has antibacterial and hemostatic properties, and is composed of an injectable formulation suitable for use in minimally invasive surgery, laparoscopic surgery or the like. The anti-adhesion polymer composition capable of supporting growth factor comprises: 24-50 wt % of a polyethyleneglycol-polypropyleneglycol-polyethyleneglycol (PEG-PPG-PEG) block copolymer having a polyethyleneglycol (PEG) content of 65-85 wt % and a molecular weight of 6,000-20,000 Da; 0.03-5 wt % of gelatin; 0.03-5 wt % of chitosan; and distilled water. 1. An anti-adhesion polymer composition capable of supporting growth factor , the composition comprising: 24-50 wt % of a polyethyleneglycol-polypropyleneglycol-polyethyleneglycol (PEG-PPG-PEG) block copolymer having a polyethyleneglycol (PEG) content of 65-85 wt % and a molecular weight of 6 ,000-20 ,000 Da; 0.03-5 wt % gelatin; 0.03-5 wt % of chitosan; and distilled water.2. The anti-adhesion polymer composition of claim 1 , wherein the block copolymer is composed of two kinds of block copolymers having different PEG contents.3. The anti-adhesion polymer composition of claim 2 , wherein the cont or each of the block copolymers in the composition is 12-25 wt %.4. The anti-adhesion polymer composition of claim 1 , further comprising glycerol as a stabilizer for suppressing phase separation of the composition.5. The anti-adhesion polymer composition of claim 1 , further comprising at least one growth factor selected from among epidermal growth factor (EGF claim 1 , beta-urogastrone) claim 1 , heparin-binding EGF-like growth factor (HB-EGF) claim 1 , transforming growth factor-α (TGF-α) and fibroblast growth factors (FGFs). The present invention relates to an anti- ...

Adhesive Composition

The invention is directed to an adhesive complex coacervate composition, to a method of physically crosslinking an adhesive complex coacervate composition, to a method for adhering a tissue defect in a subject, and to the use of an adhesive complex coacervate composition. The adhesive complex coacervate composition of the invention comprises a polycation and a polyanion, wherein said polycation and polyanion together comprise on average at least two thermoresponsive moieties per polymer chain, said thermoresponsive moieties exhibiting a lower critical solution temperature, wherein said polycation comprises 5-70 mol % of thermoresponsive moieties and/or wherein said polyanion comprises 5-70 mol % of thermoresponsive moieties, and wherein said polycation and/or said polyanion is a graft or block copolymer comprising said thermoresponsive moieties.

Intervertebral fusion device comprising an intervertebral stabilising screw and a composition for bone remodelling

The invention relates to an intervertebral fusion device comprising an intervertebral stabilizing screw and a composition for bone remodeling. The intervertebral stabilizing screw comprises: a main body with an axial through-hole and a distal thread that is secured to the bone, located at a distal end of the main body; a hollow proximal secondary body that can slide along the length of the main body; and a travel stop for the proximal secondary body, located on an outer surface of the main body. According to the invention, the proximal secondary body also includes an external thread for securing to the bone, and the main body comprises at least one fill hole, located between the distal thread and the travel stop, for connecting an intervertebral space to the aforementioned axial hole.

STABLE COMPOSITIONS COMPOSED OF A RADIOPAQUE AGENT AND CYANOACRYLATE MONOMER AND APPLICATIONS THEREOF

Described herein are compositions composed of a radiopaque agent and a cyanoacrylate monomer. These compositions cure in situ when administered to a subject and, thus, have numerous biomedical applications. The presence of the radiopaque agent allows the practitioner to visualize the compositions during and immediately after administration to the subject. The compositions are non-toxic and shelf-stable, and can be sterilized to prevent microbial growth. The compositions can be pre-mixed prior to sale and distribution, reducing the need for special training in their use. 2. The composition of claim 1 , wherein the radiopaque agent comprises two groups comprising the structure I.4. The composition of claim 3 , wherein Rand Rare the same alkyl group.5. The composition of claim 4 , wherein Rand Rare each a Cto Calkyl group.6. The composition of claim 4 , wherein Rand Rare each methyl claim 4 , ethyl claim 4 , propyl claim 4 , butyl claim 4 , pentyl claim 4 , hexyl claim 4 , heptyl claim 4 , or octyl.7. The composition of claim 1 , wherein the cyanoacrylate monomer is an alkyl cyanoacrylate monomer claim 1 , a cycloalkyl cyanoacrylate monomer claim 1 , an allyl cyanoacrylate monomer claim 1 , an aryl cyanoacrylate monomer claim 1 , an aralkyl cyanoacrylate monomer claim 1 , a carboxy alkyl cyanoacrylate monomer or an iodo-substituted cyanoacrylate monomer.8. The composition of claim 1 , wherein the cyanoacrylate monomer is a C-Calkyl cyanoacrylate monomer.9. The composition of claim 1 , wherein the alkyl cyanoacrylate monomer is butyl cyanoacrylate monomer.10. The composition of claim 3 , wherein the cyanoacrylate monomer is butyl cyanoacrylate monomer and Rand Rare the same alkyl group.11. The composition of claim 10 , wherein Rand Rare each methyl claim 10 , ethyl claim 10 , propyl claim 10 , butyl claim 10 , pentyl claim 10 , heptyl claim 10 , or octyl.12. The composition of claim 1 , wherein the cyanoacrylate monomer is from 30 wt % to 90 wt % of the composition.13. ...

Spinal disk regenerative composition and method of manufacture and use

The present invention provides a novel way to replenish the disc using retooled disc compositions to repair degenerative discs. There is no better source of proteoglycans than the actual disc material ( 6 ) itself. To this end, there has been developed a technique to remove the nucleus pulposus and retool the morphology of the nucleus pulposus to create a powder material ( 10 ) that is dry and can be stored at room temperature for long periods of time. This powder ( 10 ) can then be reconstituted with a variety of fluids, the most suitable being normal saline or lactated ringers to form a flowable mixture ( 20 ).

SURGICAL METHODS EMPLOYING PURIFIED AMPHIPHILIC PEPTIDE COMPOSITIONS

Compositions, methods and delivery devices (e.g., pre-filled syringes) for controlling bleeding during surgical procedures are provided, wherein the compositions are characterized as having an aqueous formulation that is capable of adopting a gelled state upon contact with bodily fluids and/or blood of a patient (i.e., physiological conditions).

VITAMIN E PHOSPHATE OR ACETATE FOR USE IN THE TREATMENT AND PREVENTION OF BIOFILM INFECTIONS

The present invention concerns vitamin E selected among vitamin E phosphate, optionally in combination with methylene blue, and/or vitamin E acetate in combination with methylene blue for use in the treatment and prevention of biofilm infections or as an antifungal agent by means of the application of vitamin E as defined above or in combination with a biocompatible vector on inert or living surfaces. 118-. (canceled)19. Vitamin E for use in the treatment and prevention of biofilm infections , such as bacterial or fungal biofilm , wherein the vitamin E is selected from the group consisting of vitamin E phosphate , optionally in combination with methylene blue , and/or vitamin E , such as vitamin E acetate , in combination with methylene blue.20Escherichia coliPseudomonas aeruginosaStaphylococcus aureusStaphylococcus epidermidisCandida albicans. Vitamin E according to claim 19 , wherein the biofilm is a gram-negative bacterial biofilm claim 19 , such as biofilms formed by and claim 19 , a gram-positive bacterial biofilm containing bacteria such as biofilms formed by and claim 19 , or a fungal biofilm such as a biofilm formed by for example.21. Vitamin E according to claim 19 , wherein vitamin E phosphate and/or vitamin E such as vitamin E acetate for example is used at a concentration of up to 100 w/v % claim 19 , preferably ranging from 1 to 50 w/v % and even more preferably from 5 to 20 w/v %.22. Vitamin E according to claim 19 , wherein the vitamin E is applied on living surfaces such as surfaces of wounds claim 19 , of the skin claim 19 , joints claim 19 , bones claim 19 , and of internal tissues for example.23. Use of vitamin E as defined in against the formation of a biofilm on inert surfaces by applying said vitamin E on to the inert surfaces claim 19 , such as on the surfaces of prostheses or implantable biomaterials claim 19 , of material for osteosynthesis and fracture fixation claim 19 , of catheters or endovascular devices claim 19 , bone cements claim 19 ...

EMBOLIC MICROSPHERES

In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles. 1. Injectable particles comprising at least one pH-altering agent that is configured to be released from the injectable particles in vivo upon embolization of an intratumoral artery of a tumor with the injectable particles.2. The injectable particles of claim 1 , wherein the injectable particles are configured such that claim 1 , upon embolization of the intratumoral artery of the tumor with the injectable particles claim 1 , the injectable particles release the pH-altering agent such that a microenvironment is created in a vascular bed of the tumor downstream of the injectable particles that has a pH that is higher than a pH that would otherwise exist in the absence of the pH-altering agent.3. The injectable particles of claim 1 , wherein the injectable particles are spherical or non-spherical particles.4. The injectable particles of claim 1 , wherein the injectable particles range from 20 to 1500 microns in diameter.5. The injectable particles of claim 1 , wherein the pH-altering agent is (a) a basic agent having a pH value of 7.5 or more claim 1 , (b) a buffering agent having a pKa value of 7.6 or more claim 1 , or a combination of (a) and (b).6. The injectable particles of claim 1 , wherein the pH-altering agent is (a) a basic agent having a pH value ranging from 7.5 to 10 claim 1 , (b) a buffering agent having a pKa value ranging from 8 to 35 claim 1 , or (c) a combination of (a) and (b).7. The ...

Antimicrobial Adhesives Having Improved Properties

Adhesive compositions exhibiting antimicrobial properties, good stability, long shelf lives and enhanced release of antimicrobial agents are described. In certain versions, the compositions also exhibit relatively high fluid handling capacities. The adhesive compositions inhibit microbial growth by more than 2 log after 24 hours contact and particularly more than 3.5 log after 6 hours contact. Also described are various medical articles using such adhesives and related methods. 1. An antimicrobial adhesive composition comprising chlorhexidine and at least one non-gelling disintegrant;wherein the adhesive composition inhibits microbial growth by more than 2 log throughout a 7-day contact time period;wherein at least one non-gelling disintegrant is microcrystalline cellulose; andwherein the non-gelling disintegrant is 15% to 45% of the antimicrobial adhesive composition.2. The adhesive composition of wherein the adhesive composition exhibits a static absorption of at least about 5 g/m2/24 hours.3. The adhesive composition of wherein the adhesive composition also exhibits a moisture vapor transmission rate (MVTR) of at least 400 g/m2/24 hours.5. The medical article of wherein the adhesive composition exhibits a static absorption of at least about 5 g/m2/24 hours.6. The medical article of wherein the adhesive composition also exhibits a moisture vapor transmission rate (MVTR) of at least 400 g/m2/24 hours.8. The adhesive composition of wherein the adhesive composition is a pressure sensitive adhesive.9. The adhesive composition of wherein the adhesive component comprises an acrylic-based adhesive.10. The adhesive composition of wherein the adhesive component comprises a silicone-based adhesive.11. The adhesive composition of wherein the adhesive component comprises a rubber-based adhesive.12. The adhesive composition of wherein the adhesive component comprises a polyurethane-based adhesive.13. The adhesive composition of further comprising at least one agent selected ...

Tiny Bone Defect Repairing Material, Matrix Material Thereof and Producing Method Thereof

The present invention provides a producing method for a tiny bone defect repairing material. The invention solves the problems that the setting time is too long to cause bad mechanical property in conventional bone cements and also remains bioactivities and water absorb ability. The invention has no cytotoxicity and enables to stimulate cells growth.

BIMODAL TREATMENT METHODS AND COMPOSITIONS FOR GASTROINTESTINAL LESIONS WITH ACTIVE BLEEDING

The present invention relates to a long-lasting medical product for protecting or treating a lesion in the gastrointestinal tract. The medical product includes a protective covering, wherein the medical product upon application at and about the site of the lesion adheres to the gastrointestinal tissue and is capable of remaining at and about the site of the lesion for a time sufficient to allow the lesion to heal or be treated. 120-. (canceled)21. A method for protecting and treating a lesion with active bleeding in the gastrointestinal tract , comprising:directly applying a hemostatic composition comprising a hemostatic agent at and about a site of the lesion in the gastrointestinal tract in the amount and for a time sufficient to stop the active bleeding; andonce the active bleeding has stopped or slowed, directly applying a protective covering comprising an adhesive agent on top of and about at least a portion of the previously applied hemostatic composition, wherein the protective covering upon application on top of and about at least a portion of the hemostatic composition is in direct contact with both the hemostatic composition and tissue surrounding the lesion, provides a sustained protective barrier, and is capable of remaining at and about the site of the lesion for a minimum of 30 minutes.22. The method of claim 21 , wherein the step of applying the hemostatic composition comprises spraying claim 21 , ejecting or spreading the hemostatic agent at and about the site of the lesion with the active bleeding.23. The method of claim 21 , wherein the step of applying the protective covering comprises spraying claim 21 , ejecting or spreading the protective covering on top of and about at least a portion of the previously applied hemostatic composition at and about the lesion site in the gastrointestinal tract.24. The method of claim 21 , wherein the adhesive agent is in a powder claim 21 , a liquid or a gel form.25. The method of claim 21 , wherein the adhesive ...

Ostomy device

Disclosed is an ostomy device with an adhesive wafer for attachment to a skin surface (S) of a user and a collecting bag () or collecting output from a stoma. The collecting bag is connected to the adhesive wafer, and the adhesive wafer has a through-going hole () for accommodating the stoma () of the user. The adhesive wafer includes a backing layer (), a first switchable adhesive composition (), a second absorbent adhesive composition (), and a release liner, and the second adhesive layer has a central portion with a first thickness and an edge portion with a second thickness, the first thickness being larger than the second thickness. 125.-. (canceled)26. An ostomy device providing a hole adapted for placement around a stoma of a user , the ostomy device comprising:an adhesive wafer having a backing layer, a switchable adhesive layer applied to the backing layer, and an absorbent adhesive layer applied to the switchable adhesive layer, where the backing layer defines a distal surface of the ostomy device and is adapted to receive a collecting bag for collection of output from the stoma;wherein the hole is formed through the backing layer, the absorbent adhesive layer, and the switchable adhesive layer;wherein the switchable adhesive layer is a ring-shaped annular band having a lateral extent that extends from an edge of the hole to an outermost perimeter of the ostomy device and the absorbent adhesive layer is formed around an entirety of the hole and extends from the edge of the hole to a rim that is located a radial distance away from the edge of the hole, where the radial distance is less than the outermost perimeter of the ostomy device;wherein the absorbent adhesive layer has a first thickness measured at the edge of the hole and a second thickness measured at the rim, and the first thickness is larger than the second thickness;wherein the switchable adhesive layer comprises a photoinitiator reactive to visible light;wherein the absorbent adhesive layer ...

Synthetic mechanical hemostatic composition, method of making and use thereof

A biocompatible, polymeric composition is disclosed. The composition comprises a base polymer comprising (i) a prepolymer comprising para-dioxanone (PDO) and trimethylene carbonate (TMC); and (ii) an end-graft polymer chain comprising a polylactone. Also disclosed are a method for treating bleeding from bone or bony structures using the composition, a method for filling a void or correct a defect in a bone using the composition, and a method for producing the biocompatible, polymeric composition of the present application.

Photoactivated crosslinking of a protein or peptide

A method of crosslinking a protein or peptide for use as a biomaterial, the method comprising the step of irradiating a photoactivatable metal-ligand complex and an electron acceptor in the presence of the protein or peptide, thereby initiating a cross-linking reaction to form a 3-dimensional matrix of the biomaterial.

Sealing agent for genitals

The present invention aims to provide a cervical canal sealant that can be used as a sealant to stop bleeding in the uterus and vaginal discharge, particularly, a cervical canal sealant that can block the cervical canal to inhibit amniotic fluid leakage and that can also be peeled off without damaging reproductive tissue. The present invention relates to a sealant for reproductive organs in which a cured product (X) at 25° C. has a storage modulus G′ of 200 to 2,000 kPa, the cured product (X) being a cured product obtained by curing the sealant for reproductive organs to a thickness of 120 to 150 μm.

Polymeric treatment compositions

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological pH solution; wherein the biocompatible polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

Antipathogenic Compositions

Compositions useful as bone fillers or dental composites are provided which may include a sterilizing agent. 1. A composition comprising one or more polymerizable compounds , one or more glass filler compounds , one or more sterilizing agents , one or more free radical polymerization initiators , one or more polymerization accelerators and one or more free-radical scavenger compounds.2. The composition of wherein the one or more polymerizable compounds includes an acrylate compound.3. The composition of wherein the acrylate compound includes one or more of bisphenol A glycidyl dimetharcylate claim 2 , ethoxylated bis-phenol A dimethacrylate or triethylene glycol dimethacrylate.4. The composition of wherein the one or more glass filler compounds includes one or more of barium boroalumina silicate or fumed silica.5. The composition of wherein the one or more sterilizing agents includes one or more of organic acids claim 1 , benzoic acid claim 1 , scorbic acid claim 1 , organic esters claim 1 , parabens claim 1 , methyl claim 1 , ethyl claim 1 , propyl and butyl esters of para-(4)-hydroxy benzoic acid claim 1 , quaternary ammonium compounds claim 1 , biguanides claim 1 , chlorhexidine claim 1 , chlorhexidine diacetate claim 1 , chlorhexidine gluconate claim 1 , organomercurial compounds claim 1 , phenylmercuric nitrate claim 1 , phenyl mercuric acetate claim 1 , phenyl mercuric acid claim 1 , merthiolate claim 1 , alcohols claim 1 , ethanol claim 1 , methanol claim 1 , propan-1-ol claim 1 , propan-2-ol claim 1 , phenyl ethanol claim 1 , aldehyde compounds claim 1 , glutaraldehyde claim 1 , formaldehyde claim 1 , glyoxal claim 1 , malonaldehyde claim 1 , succinaldehyde claim 1 , adipaldehyde claim 1 , halogen compounds claim 1 , iodine claim 1 , iodine compounds claim 1 , iodophors claim 1 , chlorine claim 1 , chlorine compounds claim 1 , chlorine releasing compounds claim 1 , calcium hypochlorite claim 1 , sodium dichloroisocyanusate claim 1 , hypochlorous acid claim 1 ...

ADHESIVE FOR HARD TISSUE BONDING, ADHESIVE KIT FOR HARD TISSUE BONDING, AND BONE CEMENT

An adhesive for hard tissue bonding which has a sufficient pot life and excellent biocompatibility and is replaced with bone over time, and an adhesive kit for hard tissue bonding are provided. In addition, bone cement is provided which has excellent biocompatibility and is replaced with bone over time. An adhesive for hard tissue bonding includes: a cyanoacrylate monomer; and beta-tricalcium phosphate or hydroxyapatite. An adhesive kit for hard tissue bonding includes: a liquid agent containing a cyanoacrylate monomer; and a powdery agent containing beta-tricalcium phosphate or hydroxyapatite. Bone cement includes: a cyanoacrylate polymer; and beta-tricalcium phosphate or hydroxyapatite. 1. An adhesive for hard tissue bonding , the adhesive comprising:a cyanoacrylate monomer, andbeta-tricalcium phosphate or hydroxyapatite.2. The adhesive for hard tissue bonding according to claim 1 ,wherein in the beta-tricalcium phosphate, a part of a calcium position in a crystal is replaced with a magnesium ion by dissolution and some vacancies existing in a crystalline structure are replaced with sodium ions by dissolution.3. The adhesive for hard tissue bonding according to claim 1 ,wherein in the beta-tricalcium phosphate, a part of a phosphorus position in a crystal is replaced with a silicon ion by dissolution.4. The adhesive for hard tissue bonding according to claim 3 , the adhesive further comprising:less than or equal to 5 mol % of the silicon ions with respect to all anion positions.5. The adhesive for hard tissue bonding according to claim 1 ,wherein an average particle diameter of the beta-tricalcium phosphate and the hydroxyapatite is less than or equal to 100 μm.6. The adhesive for hard tissue bonding according to claim 1 ,wherein an average particle diameter of the beta-tricalcium phosphate and the hydroxyapatite is less than or equal to 50 μm.7. The adhesive for hard tissue bonding according to claim 1 ,wherein the beta-tricalcium phosphate and the hydroxyapatite ...

Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods ofpreparing and using the same

Polymeric particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene and/or a derivative thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Particles of the present invention may further be provided as color-coded microspheres or nanospheres to allow ready identification of the sized particles in use. Such color-coded microspheres or nanospheres may further be provided in like color-coded delivery or containment devices to enhance user identification and provide visual confirmation of the use of a specifically desired size of microspheres or nanospheres.

NOVEL POLYPEPTIDES AND MEDICAL USES THEREOF

The present invention provides polypeptides comprising or consisting of an amino acid sequence derived from collagen type VI or a fragment, variant, fusion or derivative thereof, or a fusion of said fragment, variant of derivative thereof, wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms. Related aspects of the invention provide corresponding isolated nucleic acid molecules, vectors and host cells for making the same. Additionally provided are pharmaceutical compositions comprising a polypeptide of the invention, as well as methods of use of the same in the treatment and/or prevention of microbial infections and in wound care. Also provided are a method of killing microorganisms in vitro and a medical device associated with the pharmaceutical composition. 1. A polypeptide comprising or consisting of an amino acid sequence derived from collagen type VI , or a fragment , variant , fusion or derivative thereof , or a fusion of said fragment , variant of derivative thereof ,wherein the polypeptide, fragment, variant, fusion or derivative is capable of killing or attenuating the growth of microorganisms.2. A polypeptide according to wherein the microorganisms are selected from the group consisting of bacteria claim 1 , mycoplasmas claim 1 , yeasts claim 1 , fungi and viruses.3. A polypeptide according to any one of the preceding claims wherein the polypeptide is capable of binding to the membrane of the microorganism.4. A polypeptide according to any one of the preceding claims wherein the polypeptide is capable of causing membrane disruption of the microorganisms.5. A polypeptide according to any one of the preceding claims which is capable of promoting wound closure.6. A polypeptide according to any one of the preceding claims claim 1 , wherein the polypeptide is capable of exhibiting an antimicrobial effect greater than or equal to that of LL-37.7. A polypeptide according to any one of ...

POLY (IONIC LIQUID) COMPOSITIONS AND THEIR USE AS TISSUE ADHESIVES

The present invention relates to the discovery of methods of treating a wound in a subject in need thereof. In certain embodiments, the method comprises contacting the wound with a composition comprising gelatin methacrylate and choline acrylate, and then polymerizing the composition to form a polymerized composition having a plurality of choline acrylate functionalized gelatin methacrylate units. 1. A method of treating a wound in a subject in need thereof , the method comprising:(a) contacting the wound with a composition comprising:a polymer selected from the group consisting of gelatin methacrylate (GelMa) and poly(ethylene glycol) diacrylate (PEGDA);choline acrylate; andat least one photoinitiator; and(b) exposing the composition to at least one wavelength of light capable of activating the at least one photoinitiator, thereby polymerizing the composition.2. The method of claim 1 , wherein the composition comprises about 1:4 to about 4:1 choline acrylate to polymer.3. (canceled)4. The method of claim 1 , wherein at least one photoinitiator is selected from the group consisting of eosin Y claim 1 , 2-hydroxy-2-methylpropiophenone claim 1 , 2-methyl-4′-(methylthio)-2-morpholinopropiophenone claim 1 , lithium phenyl-2 claim 1 ,4 claim 1 ,6-trimethylbenzoylphosphinate (LAP) claim 1 , and 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure).5. The method of claim 1 , wherein the composition further comprises at least one additional compound selected from the group consisting of triethanolamine (TEOA) and N-vinylcaprolactam (VC).6. (canceled)7. The method of claim 1 , wherein the composition comprises about 10% to about 20% (w/v) choline acrylate.8. The method of claim 1 , wherein the composition comprises about 10% to about 30% (w/v) polymer.9. The method of claim 4 , wherein the composition comprises at least one of:about 0.1 mM eosin Y;0.5% (w/v) LAP;about 1.5% (w/v) TEOA; orabout 1% (w/v) VC.10. (canceled)11. (canceled)12. (canceled)13. The method of ...

COMPOSITION FOR HARD TISSUE REPAIR AND KIT FOR HARD TISSUE REPAIR

The application discloses a composition for hard tissue repair comprising a monomer (A), a polymer powder (B) and a polymerization initiator (C), wherein the polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more, and the cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 75 cumulative % or less, as well as, a kit for hard tissue repair comprising three or more members, in which each of the components of the monomer (A), the polymer powder (B) and the polymerization initiator (C) contained in this composition for hard tissue repair are divided and contained in the members in an optional combination. 1. A composition for hard tissue repair comprising a monomer (A) , a polymer powder (B) and a polymerization initiator (C) , whereinthe polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more, andthe cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 75 cumulative % or less.2. The composition for hard tissue repair according to claim 1 , wherein the cumulative ratio of powder particles having aspect ratios of 1.00 or more and less than 1.10 in all of the powder particles contained in the composition for hard tissue repair is 2.5 cumulative % or more claim 1 , and 65 cumulative % or less.3. The composition for hard tissue repair according to claim 1 , wherein the polymer powder (B) comprises a polymer powder (B-x) having an aspect ratio of 1.10 or more and 1.90 or less claim 1 , and the aspect ratio of all of the polymer powder (B) is 1.11 or more and 1.80 or less.4. The composition for hard tissue repair according to claim 1 , wherein the monomer (A) is a (meth)acrylate-based monomer.5. The composition for hard tissue repair according to claim 1 , ...

POLYMERIC TREATMENT COMPOSITIONS

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological solution; wherein the biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use. 1. A polymeric composition comprising: 'a first monomer including a biodegradable linkage to a visualization agent, and a second monomer including at least one hydroxyl group; and', 'a substantially stable biocompatible polymer comprising a reaction product ofwherein the substantially stable biocompatible polymer is dissolved in a solution.2. The polymeric composition of claim 1 , wherein the visualization agent includes at least one aromatic ring.3. The polymeric composition of claim 2 , wherein the at least one aromatic ring at least one iodine atom.4. The polymeric composition of claim 1 , wherein the solution is a non-physiological solution.5. The polymeric composition of claim 4 , wherein the non-physiological solution is a water miscible solvent.6. The polymeric composition of claim 5 , wherein the concentration of the substantially stable biocompatible polymer in the water miscible solvent is about 1% to about 50%.7. The polymeric composition of claim 1 , wherein the second monomer is hydroxyethyl methacrylate.8. The polymeric composition of claim 1 , wherein the biodegradable linkage is Seq. ID 1 claim 1 , Seq. ID 2 claim 1 , Seq. ID 3 claim 1 , Seq. ID 4 claim 1 , Seq. ID 5 claim 1 , Seq. ID 6 claim 1 , Seq. ID 7 claim 1 , Seq. ID 8 claim 1 , Seq. ID 9 claim 1 , Seq. ID 10 claim 1 , Seq. ID 11 claim 1 , or Seq. ID 12.9. The polymeric composition of claim 1 , wherein the biodegradable linkage is an ester or a polyester.10. The polymeric composition of claim 1 , wherein the substantially stable biocompatible polymer is a reaction product of 2-oxo-2-(1-oxo-1-(1-oxo-1-(2 claim 1 ,4 ...

POROUS POLYMER COMPOSITES

Porous polymer composites and methods of preparing porous polymer composites are provided herein. In some embodiments, a method for preparing porous polymer composites may include mixing a first polymer with a solvent and a particulate filler to form a first polymer composition, wherein the amount of particulate filler in the first polymer composition is below a mechanical percolation threshold; and removing the solvent from the first polymer composition to concentrate the first polymer and particulate filler into a second polymer composition having a porous structure, wherein the particulate filler concentration in the second polymer composition is increased above the mechanical percolation threshold during solvent removal. 1. A method of forming a porous polymer composition , comprising:mixing a first polymer with a solvent and a particulate filler to form a first polymer composition, wherein the amount of particulate filler in the first polymer composition is below a mechanical percolation threshold; andremoving the solvent from the first polymer composition to concentrate the first polymer and particulate filler into a second polymer composition having a porous structure, wherein the particulate filler concentration in the second polymer composition is increased above the mechanical percolation threshold during solvent removal.2. The method of claim 1 , wherein the first polymer is at least one of a thermoplastic claim 1 , a physically cross-linked polymer network claim 1 , or a chemically cross-linked polymer network.3. The method of claim 1 , wherein the particulate filler concentration in the first polymer composition is about 2 volume % to about 55 volume %.4. The method of claim 1 , wherein the particulate filler concentration in the second polymer composition is about 3 volume % to about 95 volume % relative to a total volume of solids in the second polymer composition.5. The method of claim 1 , wherein the solvent is removed by at least one of evaporation ...

TREATMENT FOR BILE LEAKAGE

Materials and methods for treating bile leakage are disclosed. A peptide comprising between about 7 amino acids to about 32 amino acids may be introduced to a target site. The peptide may undergo self-assembly upon adjustment of a pH level of the solution to a physiological pH level. 1. A method of treating a bile leakage in a subject comprising:positioning an end of a delivery device in a target area of the bile leakage in which an occlusion is desired;administering through the delivery device a solution comprising a self-assembling peptide comprising between about 7 amino acids and about 32 amino acids in an effective amount and in an effective concentration to form a hydrogel under conditions surrounding the bile leakage to provide an occlusion of the bile leakage;removing the delivery device from the target area of the bile leakage.2. The method of claim 1 , further comprising visualizing a region comprising at least a portion of the target area surrounding the bile leakage.3. The method of claim 2 , wherein visualizing the region comprises visualizing the region during at least one of:identifying the target area of the bile leakage;positioning the end of the delivery device in the target area;administering the solution;removing the delivery device; andmonitoring the bile leakage after removing the delivery device.4. The method of claim 3 , wherein visualizing the region provides for selective administration of the solution to the target area of the bile leakage.5. The method of claim 3 , further comprising visualizing the region in a time period of about one minute subsequent to administering the solution.6. The method of claim 5 , further comprising visualizing the region in a time period of about three minutes subsequent to administering the solution.7. The method of claim 6 , further comprising visualizing the region in a time period of about one week subsequent to administering the solution.8. The method of claim 1 , wherein at least one of the effective ...

Injectable Biodegradable Bone Matrix for Multiple Myeloma Lesion Augmentation and Osteoporosis

Bone filler compositions, methods of making and using the same, and methods of treating osteoporosis and cancer-induced bone defects, are described.

EMBOLIZATION PARTICULATES FOR OCCLUDING A BLOOD VESSEL

Injectable embolization particulates (e.g., particles, microstructures, beads) employed in embolization procedures, for facilitating blood vessel occlusion. Exemplary embolization particulates for occluding a blood vessel include a plurality of embolization beads, each bead having a plurality of outwardly protruding portions, wherein, upon a first one and a second one of the beads accumulating against a boundary of the blood vessel, protruding portions of the first bead are configured to intermesh with protruding portions of the second bead, so as to occlude the blood vessel. Also disclosed are compositions of embolization particulates including a plurality of shaped embolization beads, and methods for embolizing or occluding a blood vessel using embolization particulates or compositions thereof. Embolization particulates have particular shapes for facilitating blood vessel occlusion while preventing or diminishing back flow (reflux) of embolic material, and may be coated or impregnated with therapeutic agents or radioactive isotopes, for increasing desirable therapeutic effects. 1. Embolization particulates suitable for occluding a blood vessel , the embolization particulates comprising:a plurality of embolization beads, each of said embolization beads comprises:a plurality of outwardly protruding portions, wherein, upon a first one and a second one of said embolization beads accumulating against a boundary of the blood vessel, said protruding portions of said first embolization bead are configured to intermesh with said protruding portions of said second embolization bead, so as to occlude the blood vessel.2. The embolization particulates of claim 1 , wherein said embolization beads are configured to resist or/and dissipate forces generated by claim 1 , or originating from claim 1 , fluid flow during an embolization procedure.3. The embolization particulates of claim 1 , wherein at least one of said outwardly protruding portions is hydrodynamically shaped to ...

FILMS AND METHODS OF MANUFACTURE

Embodiments of the present disclosure are directed to perforated polymer films and methods of making the same. In some embodiments, the films are for use with implantable medical devices. In one embodiment there is a flexible body including a polymer film having a first surface and an opposing second surface, the film having a plurality of apertures extending from the first surface to the second surface and a plurality of raised lips protruding from the first surface such that each of the plurality of apertures is surrounded by a one of the plurality of raised lips. In one embodiment, the film comprises a single layer, and in another embodiment, the film can comprise a plurality of layers. In certain embodiments, the film can comprise an adhesive layer. In another embodiment, one or more of the layers may be a drug containing layer and/or a rate controlling layer for drug release. 1. A method of forming a multi-layer film for drug delivery comprising:placing a first polymer solution into a mold having a plurality of protrusions extending from a bottom of the mold;urging the first polymer solution around each of the plurality of protrusions;placing one or more additional polymer solutions into the mold; and,solidifying the first polymer solution and the one or more additional polymer solutions;wherein a multi-layer film having a plurality of apertures is formed; and,wherein at least one of the first polymer solution or the one or more additional polymer solutions comprises a drug.2. The method of claim 1 , wherein the step of placing one or more additional polymer solutions into the mold occurs prior to the step of urging claim 1 , such that urging the polymer solution includes urging the first polymer solution and the one or more polymer solutions.3. The method of claim 1 , wherein the step of solidifying the polymer solution occurs both prior to and after the step of placing one or more additional polymer solutions into the mold.4. The method of claim 1 , wherein ...

COMPOSITIONS AND MEDICAL DEVICES COMPRISING ANTI-MICROBIAL PARTICLES

This invention relates to compositions and medical devices comprising anti-microbial active particles, for inhibiting microbial growth. This invention further provides methods of making such compositions and medical devices. 3. The composite of claim 1 , wherein the particles are dispersed in the polymeric material.4. The composite of claim 1 , wherein the core of the particles comprises silica.5. The composite of claim 4 , wherein the silica is selected from the group consisting of amorphous silica claim 4 , dense silica claim 4 , aerogel silica claim 4 , porous silica claim 4 , mesoporous silica and fumed silica.6. The composite of claim 1 , wherein the inorganic polymer is selected from the group consisting of silicone polymers ceramics claim 1 , metals claim 1 , and combinations thereof.7. The composite of claim 1 , wherein the inorganic core is polyhedral oligomeric silsesquioxane (POSS).8. The composite of claim 1 , wherein the weight ratio of the anti-microbial particles which are represented by structure (1) to the polymeric material is between 0.25-5%.9. The composite of claim 1 , wherein the particles are a mixture of different particles.10. The composite of claim 1 , wherein said composition is capable of filling of tooth decay cavities claim 1 , is a dental restorative endodontic filling material for filling root canal space in root canal treatment claim 1 , or is selected from the group consisting of a dental restorative material intended for provisional and final tooth restorations or tooth replacement claim 1 , a dental inlay claim 1 , a dental onlay claim 1 , a crown claim 1 , a partial denture claim 1 , a complete denture claim 1 , a dental implant claim 1 , a dental implant abutment claim 1 , and a cement intended for permanently cementing crowns bridges claim 1 , onlays claim 1 , partial dentures and orthodontic appliances onto tooth enamel and dentin.11. The composite of claim 1 , wherein the anti-microbial active groups have a surface density of ...

Bioactive Medical Ceramic Cement

Bioactive, ceramic medical cements and methods for its use in treatment of bones and teeth in mammals are disclosed. This cement is non-exothermic and non-toxic, based upon setting of hydraulic ceramic compounds containing calcia, alumina, and silica phases. The self-hardening cement sets in vivo and in high humidity environments, and can be used in vivo without being easily washed out of the site. It also has dimensional stability, is resistant to acids present in an infection site or supragingivally, and has biocompatibility advantages of low inflammation and the formation of calcification layers in direct apposition to body tissue. Options include the addition of various radiopaque materials, and a variety of delivery systems including powder and liquid, capsule or pouch delivery, multiple pastes, or a unitary paste. 1. A biocompatible , osteogenic , bioactive , antimicrobial , and hydraulic self-setting ceramic cement composition for use in diverse medical , dental , and veterinary applications , including form restoration and device attachment , said cement composition characterized by:a fine ceramic powder phase having calcia, alumina, and silica compounds that are hydraulic, said ceramic powder phase having a maximum particle size less than 20 μm and a maximum median particle size of 9 μm; anda fine radiopaque powder, wherein when said fine ceramic powder phase is combined with said fine radiopaque powder into a powder mixture, and further wherein when said powder mixture is placed in contact with at least one aqueous fluid, said powder mixture begins to hydraulically set into a hardened cement mass while experiencing less than 0.1% linear expansion, has increased resistance to acids present at the site where it is applied, inherently forms calcific layers in direct apposition to body tissue at the site where it is applied, and sets at body temperature and room temperature without raising the local temperature of the site where it is applied during its ...

EMBOLIZATION PARTICULATES FOR OCCLUDING A BLOOD VESSEL

Injectable embolization particulates (e.g., particles, microstructures, beads) employed in embolization procedures, for facilitating blood vessel occlusion. Exemplary embolization particulates for occluding a blood vessel include a plurality of embolization beads, each bead having a plurality of outwardly protruding portions, wherein, upon a first one and a second one of the beads accumulating against a boundary of the blood vessel, protruding portions of the first bead are configured to intermesh with protruding portions of the second bead, so as to occlude the blood vessel. Also disclosed are compositions of embolization particulates including a plurality of shaped embolization beads, and methods for embolizing or occluding a blood vessel using embolization particulates or compositions thereof. Embolization particulates have particular shapes for facilitating blood vessel occlusion while preventing or diminishing back flow (reflux) of embolic material, and may be coated or impregnated with therapeutic agents or radioactive isotopes, for increasing desirable therapeutic effects. 1. A composition comprising a plurality of beads , each of said plurality of beads having a permanent shape , furnishing the beads with a capability to resist aggregation during flow and to promote aggregation upon cessation of flow.2. The composition of claim 1 , wherein said plurality of beads are configured to resist and/or dissipate forces generated by claim 1 , or originating from claim 1 , fluid flow during an embolization procedure.3. The composition of claim 1 , wherein each of said plurality of beads are embolization beads.4. The composition of claim 1 , wherein each of said plurality of beads have a tetrahedron or tetrahedron-like shape.5. The composition of claim 1 , wherein each of said plurality of beads have a tetrapod-like shape.6. The composition of claim 1 , each of said plurality of beads having a density within the range of between about 0.8 and about 1.6 g/cm.7. The ...

Microspheres containing therapeutic agents and related methods of use

Microspheres, compositions including the microspheres, and methods of using the microspheres are disclosed herein. The microspheres can be substantially spherical and can include a copolymer of a monomer (such as an acrylic monomer) and a cyclodextrin or a derivative thereof. The microspheres can also include a therapeutic agent, such as a platinum-based drug.

COMPOSITION FOR HARD TISSUE REPAIR AND KIT FOR HARD TISSUE REPAIR

Disclosed are: a composition for hard tissue repair with excellent penetrability to an adherend such as a cancellous bone and excellent adhesion to an adherend, which comprises a monomer (A), a polymer (B), a polymerization initiator (C) and a contrast medium (X) having a volume mean particle diameter of 3 μm or more; and a kit for hard tissue repair having members in which the components of the monomer (A), the polymer (B), the polymerization initiator (C) and the contrast medium (X) contained in this composition for hard tissue repair are encased in three or more divided groups in an optional combination. 1. A composition for hard tissue repair comprising a monomer (A) , a polymer (B) , a polymerization initiator (C) and a contrast medium (X) having a volume mean particle diameter of 3 μm or more.3. The composition for hard tissue repair according to claim 1 , wherein the contrast medium (X) is barium sulfate or zirconia.4. The composition for hard tissue repair according to claim 1 , wherein the monomer (A) is a (meth)acrylate type monomer.5. The composition for hard tissue repair according to claim 1 , wherein the polymer (B) is a (meth)acrylate-based polymer.6. The composition for hard tissue repair according to claim 1 , comprising 10 to 45 parts by mass of the monomer (A) claim 1 , 54.9 to 80 parts by mass of the polymer (B) and 0.1 to 10 parts by mass of the polymerization initiator (C) (the sum of the components (A) to (C) is taken as 100 parts by mass) claim 1 , and 0.5 to 70 parts by mass of the contrast medium (X).7. The composition for hard tissue repair according to claim 1 , wherein the volume mean particle diameter of the contrast medium (X) is 3.0 to 25.1 μm.8. The composition for hard tissue repair according to claim 1 , wherein the volume mean particle diameter of all particles contained in the composition for hard tissue repair is 32 μm or less.9. A kit for hard tissue repair comprising three or more members claim 1 , in which each of the ...

POLYMER PARTICLES

Polymer particle embolics and methods of making same are described. The particle embolics can be used as embolization agents. 1. A polymer particle comprising:poly(ethylene glycol) diacrylamide, glycerol monomethacrylate, and amino ethyl methacrylate;wherein the polymer particle is spherical and has a diameter less than about 1,200 μm.2. The polymer particle of , wherein the polymer particle has a diameter between about 40 μm and about 1 ,200 μm. The polymer particle of , further comprising N ,N-methylenebisacrylamide.4. The polymer particle of claim 1 , wherein the N claim 1 ,N-methylenebisacrylamide is at a concentration of about 1% w/w.5. The polymer particle of claim 1 , wherein the poly(ethylene glycol) diacrylamide is at a concentration of about 28% w/w.6. The polymer particle of claim 1 , wherein the glycerol monomethacrylate is present at a concentration of about 68% w/w claim 1 ,7. The polymer particle of claim 1 , wherein the amino ethyl methacrylate at a concentration of about 3% w/w.8. The polymer particle of claim 1 , wherein the poly(ethylene glycol) diacrylamide is poly(ethylene glycol) diacrylamide 10 claim 1 ,000.9. The particle of claim 1 , further comprising a drug.10. A polymer particle comprising:poly(ethylene glycol) diacrylamide, 3-sulfopropyl acrylate, and amino propyl methacrylamide,wherein the polymer particle is spherical and has a diameter less than about 1,200 μm.11. The polymer particle of claim 10 , wherein the polymer particle has a diameter between about 40 pm and about 1 claim 10 ,200 μm.12. The polymer particle of claim 10 , wherein the poly(ethylene glycol) diacrylamide is at a concentration of about 40% w/w.13. The polymer particle of claim 10 , wherein the at least one monomer is 3-sulfopropyl acrylate at a concentration of about 59% w/w.14. The polymer particle of claim 10 , wherein the amino propyl methacrylamide is at a concentration of about 1% w/w.15. The polymer particle of claim 10 , wherein the poly(ethylene glycol) ...

CHEMICALLY STRENGTHENED BIOACTIVE GLASS-CERAMICS

A chemically strengthened bioactive glass-ceramic composition as defined herein. Also disclosed are methods of making and using the disclosed compositions. 1. A glass-ceramic composition , comprising:a first crystalline phase and a second crystalline phase, in combination, comprise a source of:{'sub': '2', '50 to 75 wt % SiO,'}{'sub': 2', '3, '1 to 5 wt % AlO,'}{'sub': 2', '3, '0.1 to 10% BO,'}{'sub': '2', '5 to 20 wt % LiO,'}{'sub': '2', '0.5 to 5 wt % NaO,'}{'sub': '2', '0 to 4% KO,'}{'sub': 2', '5, '0.5 to 6 wt % PO'}{'sub': '2', '0.5 to 8% ZrO, and'}{'sup': '−', '0.1 to 1.0 wt % F, based on a 100 wt % total of the composition.'}2. The glass-ceramic composition of further comprising having composition particles having ion-exchanged surfaces having a reduced lithium ion (Li) concentration and having at least one of an elevated sodium ion (Na) surface concentration claim 1 , an elevated potassium ion (K) surface concentration claim 1 , or elevated concentrations of lithium ion (Li) and sodium ion (Na) on the surface.3. The glass-ceramic composition of wherein the source is:{'sub': '2', '50 to 70 wt % SiO,'}{'sub': 2', '3, '1 to 4 wt % AlO,'}{'sub': 2', '3, '0.1 to 4% BO,'}{'sub': '2', '6 to 18 wt % LiO,'}{'sub': '2', '1 to 4 wt % NaO,'}{'sub': '2', '0 to 3% KO,'}{'sub': 2', '5, '1 to 5 wt % PO'}{'sub': '2', '1 to 6% ZrO, and'}{'sup': '−', '0.1 to 1.0 wt % F, based on a 100 wt % total of the composition.'}4. The glass-ceramic composition of further comprising having composition particles having ion-exchanged surfaces having a reduced lithium ion (Li) concentration and having at least one of an elevated sodium (Na) concentration claim 3 , an elevated potassium (K) concentration claim 3 , or an elevated concentrations of lithium ion (Li) and sodium ion (Na).5. A glass-ceramic composition claim 3 , comprising:a first crystalline phase and a second crystalline phase, in combination, comprising:{'sub': '2', '55 to 65 wt % SiO,'}{'sub': 2', '3, '2 to 4 wt % AlO,'}{'sub': ...

Dry Haemostatic Composition

Disclosed is a dry composition, which upon addition of an aqueous medium forms a substantially homogenous paste suitable for use in haemostasis procedures. The paste forms spontaneously upon addition of the liquid, hence no mechanical mixing is required for said paste to form. Further disclosed are methods of preparing said dry composition, a paste made from said dry composition and use of said paste for medical and surgical purposes. 2. The method according to claim 1 , wherein the paste prior to drying comprises from 3% w/w to 20% w/w of one or more polyols.3. The method according to claim 1 , wherein the biocompatible polymer is gelatine.4. The method according to claim 3 , wherein the gelatine is obtained from a cross-linked gelatine sponge.5. The method according to claim 1 , wherein the paste prior to freeze-drying comprises:a) from 5% w/w to 20% w/w of one or more polyols;b) from 15% w/w to 25% w/w of biocompatible polymer; andc) from 60% w/w to 80% w/w of water.6. The method according to claim 1 , wherein the dry composition comprises less than 5% w/w of water.7. The method according to claim 1 , wherein the one or more polyols is selected from sugar alcohols and sugars.8. The method according to claim 7 , wherein the one or more sugar alcohols is selected from glycol claim 7 , glycerol claim 7 , erythritol claim 7 , threitol claim 7 , arabitol claim 7 , xylitol claim 7 , ribitol claim 7 , mannitol claim 7 , sorbitol claim 7 , dulcitol claim 7 , fucitol claim 7 , iditol claim 7 , inositol claim 7 , volemitol claim 7 , isomalt claim 7 , maltitol claim 7 , lactitol or polyglycitol.9. The method according to claim 1 , wherein the one or more polyols is mannitol.10. The method according to claim 9 , where the dry composition comprises one or more further polyols.11. The method according to claim 1 , wherein the dry composition further comprises one or more bioactive agents that stimulate haemostasis or wound claim 1 , bone claim 1 , tendon and/or tissue healing. ...

COMPOSITIONS HAVING CYLINDRICAL VOLUME, METHODS, AND APPLICATORS FOR SEALING INJURIES

Disclosed are solid and frozen haemostatic materials having a rod shape and suitable applicators and plungers for application of such dressings to wounded tissue wherein said dressings consisting essentially of a fibrinogen component and a fibrinogen activator. Also disclosed are methods of treating internal wounded tissue in a mammal by applying one or more of these haemostatic materials and dressings, particularly for the treatment of injured tissue via endoscopic or minimally-invasive surgical techniques. 1. A haemostatic material for treating wounded internal tissue in a mammal comprising a cylindrical haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator wherein said cylindrical haemostaic material is made by combining liquid fibrinogen and liquid fibrinogen at about 12° C. to 0° C. and preferable between 4° C.+/−2° C. into a cylindrical mold , freezing and thereafter lyophilizing said material , wherein said fibrinogen component is present in an amount between 1 mg/cmand 75 mg/cmand said fibrinogen activator is present in an amount between about 0.01 to about 1.0 U/mg fibrinogen component; wherein said liquid combination is thereafter frozen and lyophilized.2. A method for treating wounded internal tissue in a mammal comprising applying to wounded internal tissue at least one cylindrical haemostatic material consisting essentially of a fibrinogen component and a fibrinogen activator for a time sufficient to reduce the flow of fluid from said wounded tissue and/or join or approximate said wounded tissue , wherein said haemostatic material is cast or formed from a single aqueous solution containing the fibrinogen component and the fibrinogen activator , wherein said fibrinogen component is present in an amount between 1 mg/ml and 37.5 mg/ml and said fibrinogen activator is present in an amount between about 0.01 to about 1.0 U/mg fibrinogen component; wherein said liquid combination is thereafter frozen and lyophilized. ...

Adhesive Properties

Various adhesive compositions are described which may optionally comprise one or more active agents such as pharmaceutical agents. The incorporation of one or more absorbents in combination with one or more crystallization inhibitors improves adhesive characteristics of the compositions. Also described are related methods of improving adhesive characteristics of adhesive compositions with the use of a combination of absorbent and inhibitor. Also described are related methods of using the compositions and articles incorporating such compositions.

MALLEABLE, BIODEGRADABLE HEMOSTATIC AGENT

A malleable, biodegradable hemostatic agent is provided that can be used for mechanical sealing of bleeding bone tissue, as well as a method for forming a malleable, biodegradable hemostatic agent of this type, and a medical implant having a coating that includes a malleable, biodegradable hemostatic agent of this type. The malleable, biodegradable hemostatic agent contains (a) at least one saturated glycerol-1,2,3-tri-fatty acid ester having a melting temperature above 37° C., (b) at least one filling agent present in particulate form, at least in part, and having a melting temperature above 37° C., and (c) at least one compound having a melting temperature not above 37° C. and a solubility at a temperature of 25° C. of less than 50 grams per liter of water. 1. A malleable , biodegradable hemostatic agent comprising a malleable , biodegradable composition having hemostatic properties , the composition containing a mixture of the following components:(a) at least one saturated glycerol-1,2,3-tri-fatty acid ester having a melting temperature above 37° C.;(b) at least one filling agent at least partially present in particulate form and having a melting temperature above 37° C., wherein component (b) has a solubility at a temperature of 25° C. of at least 100 grams per liter of water and is selected from the group consisting of polymers of at least one alkylene oxide and copolymers of at least one alkylene oxide; and(c) at least one compound having a melting temperature not above 37° C. and a solubility at a temperature of 25° C. of less than 50 grams per liter of water, wherein component (c) is a saturated fatty acid ester.2. The malleable claim 1 , biodegradable hemostatic agent according to claim 1 , wherein the hemostatic agent has a pH in water at a temperature of 25° C. in a range of 5.0-9.0.3. The malleable claim 1 , biodegradable hemostatic agent according to claim 1 , wherein the hemostatic agent has a pH in water at a temperature of 25° C. in a range of 5.5-8 ...

Acrylic Cements for Bone Augmentation

The embodiments relate to an injectable composition for a bone cement material comprising a dry powder component, a liquid component and a modifier configured to modify a Young's modulus of the bone cement material. The modifier is linoleic acid or a derivative thereof and is present in a concentration of 0.1 to 12 v/v of the liquid component.

Topical composition for the treatment of mucosal lesions

Topical composition for the treatment of mucosal lesions It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.

METHOD AND APPARATUS FOR DERMATOLOGICAL TREATMENT

Exemplary methods and systems can be provided for resurfacing of skin that include formation of a plurality of small holes, e.g., having widths greater than about 0.2 mm and less than about 0.7 mm or 0.5 mm, using a mechanical apparatus. Compressive and/or tensile forces can then be applied to the treated region of skin as the damage heals to facilitate hole closure, and provide enhanced and/or directional shrinkage of the treated skin area. 125-. (canceled)26. A system for producing a cosmetic effect in skin tissue , the system comprising:a plurality of round hollow coring needles configured to form a plurality of holes in a treatment region of the skin tissue, anda skin compression arrangement configured to produce and maintain a compressive stress over at least one portion of the treatment region after the plurality of holes are formed, andwherein at least one round hollow coring needle of the plurality of round hollow coring needles has an inner diameter between about 0.2 mm and about 0.5 mm.27. The system of claim 26 , wherein the system is configured to generate holes in the treatment region that extend from a surface of the skin tissue into a dermal layer of the skin tissue and remove skin tissue at an areal fraction of the treatment region between about 5% and 50%.28. The system of claim 27 , wherein at least one of the round hollow coring needles of the plurality of round hollow coring needles is structured to form a hole that extends from the surface of the skin tissue through the entire dermal layer of the skin tissue in the treatment region.29. The system of claim 27 , wherein the plurality of round hollow coring needles includes a number of round hollow coring needles between 2 and 50.30. The system of claim 29 , wherein the areal fraction of skin tissue to be removed from the treatment region is determined by at least one of the number of round hollow coring needles included in the plurality of round hollow coring needles or the inner diameters of the ...

METHOD OF TREATING A DISEASE USING A GLYCOLYTIC DEPENDENT COMPOUND

Provided are implants and a glycolytic dependent compound for use in enhancing toxicity of the glycolytic dependent compound towards a cell, tissue and/or organ e.g., a diseased cell, tissue and/or organ, wherein the implant and the glycolytic dependent compound are contacted with the cell, tissue and/or organ in a non-blended form. 1. A method of treating a diseased tissue in a subject in need using a glycolytic dependent compound , the method comprising the steps of:a) targeting the glycolytic dependent compound to the diseased tissue, by placing an implant in proximity to, adjacent to, or in direct connection with the tissue, andb) administering the glycolytic dependent compound to the subject,wherein the implant and the glycolytic dependent compound are administered in a non-blended form.2. The method of claim 1 , wherein the implant and glycolytic dependent compound are administered by different administration routes.3. The method of claim 1 , wherein the implant comprises a polymer selected from polydioxanon claim 1 , polyglycerol claim 1 , polyglycolic acid claim 1 , polycaprolactone claim 1 , polylactic acid claim 1 , polyhydroxyalkanoate claim 1 , poliglecaprone polyglactin claim 1 , polyglyconate claim 1 , polyglocolide-trimethylene carbonate claim 1 , polyhydroxybutyrate claim 1 , poly(vinylpyrrolidone) claim 1 , poly(vinyl alcohol) claim 1 , absorbable polyurethanes claim 1 , poly-p-dioxanone claim 1 , oxidized cellulose claim 1 , regenerated cellulose claim 1 , oxidized regenerated cellulose claim 1 , and any combination and co-polymer thereof.4. The method of claim 1 , wherein the implant is shaped in the form selected from a strip claim 1 , a rolled sheet claim 1 , a sponge claim 1 , a plug claim 1 , putty claim 1 , a tube claim 1 , a mesh claim 1 , a matrix claim 1 , a film claim 1 , a scaffold claim 1 , a suture claim 1 , and a fiber.5. The method of claim 1 , wherein the implant comprises a coating on at least one surface thereof.6. The method of ...

Liquid medical material

To provide a liquid medical material maintaining a colloid in a more sol form than a solid at normal temperature, having a higher function as a wound dressing material and a hemostatic material than fibrin glue, and being able to be produced safely and inexpensively. A gelatin aqueous solution including calcium at a concentration of 0.2 M or more and 1.0 M or less, and having a concentration of 5% by weight or more and 40% by weight or less, an average molecular weight of 80,000 or more and 120,000 or less, and a molecular weight distribution of 20,000 or more and 300,000 or less, and transglutaminase inducing crosslinking of the gelatin, are included. It is preferable that the calcium has a concentration of 0.2 M or more and 0.7 M or less, the gelatin has a bloom of 160 or more and 250 or less, and the transglutaminase has activity per unit of 36 U/ml to 400 U/ml.

NATURAL POLYMER BASED TISSUE ADHESIVE WITH HEALING PROMOTING PROPERTIES

A tissue adhesive with healing promotion properties formed from a mixture of natural polymers and an activating agent that enhances the adhesive properties of the natural polymer mixture is described. Use of an activating agent and a combination of the natural polymers is unique. The natural polymer tissue adhesive may be useful as a post-operative application for tonsillectomy or adenoidectomy surgery, as an internal tissue adhesive for surgery or wound repair or for application to a burn or skin donor site. For internal use, an optional treatment to improve resistance of the activated adhesive to body fluids is also described. The adhesive described not only functions as an adhesive but would also serve as a protective barrier when applied to surgery or skin sites. In addition, the natural polymers would promote healing due to the inherent properties of the polymers selected. 1. A tissue adhesive suitable for skin contact or internal use comprisinga. a mixture of natural polymers andb. an activating agent enhancing the adhesive properties of the natural properties of the natural polymer mixture;this tissue adhesive formulation is particularly useful as a protective, enhanced healing device on the surgical site created during tonsillectomy or adenoidal surgery, as an internal tissue adhesive as a replacement for sutures or staples or as a protective, enhanced healing device for burns, skin grafts or skin donor sites;2. The adhesive material described in where the natural polymers are selected from polysaccharides or partial hydrolysis derivatives or neutralization salts thereof;3. The adhesive material described in where the natural polymers selected are chitosan and an alginate;4. The method of where the natural polymers are chitosan and sodium alginate;5. The adhesive material described in where the activating agent is a dilute aqueous solution of an acid;6. The method of where the acid solution is that of a carboxylic acid;7. The method of where the carboxylic ...

APPARATUS AND METHOD OF USING IN SITU SOLIDIFYING COMPLEX COACERVATES FOR VASCULAR OCCLUSION

Described herein are the use of fluid complex coacervates that produce solid adhesives in situ to anchor medical devices such as catheters in a blood vessel. The anchored devices permit the targeted delivery of bioactive agents. The anchored devices can perform as an embolic agent by reducing or preventing blood flow in the vessel. Additionally, the embolic produced from the solid adhesive produced in situ can also include one or more bioactive agents that can be released in a controlled manner. 1. A method for anchoring a catheter in a blood vessel of a subject , the method comprising(a) inserting into a blood vessel of a subject a first catheter and a second catheter, wherein the second catheter is extended further into the vessel than the first catheter; and(b) injecting into the first catheter an in situ solidifying complex coacervate to produce an adhesive in the vessel that adheres the second catheter to the inner wall of the vessel, wherein the in situ solidifying complex coacervate comprises at least one polycation, at least one polyanion, and a salt that produces ions in water, wherein the concentration of the ions in the complex coacervate is greater than the concentration of the ions in the blood vessel.2. The method of claim 1 , wherein the first catheter and second catheter are a co-axial catheter.3. The method of claim 1 , wherein the second catheter comprises an occlusion balloon catheter.4. The method of claim 1 , wherein the first catheter and second catheter are sistered to one another.5. The method of claim 4 , wherein the diameter of the first catheter is greater than the diameter of the second catheter.6. The method of claim 5 , wherein the tip of the second catheter extends past the tip of the first catheter.7. The method of claim 1 , wherein the adhesive completely seals the vessel.8. The method of claim 1 , wherein the first catheter is removed from the vessel.9. The method of claim 1 , wherein the second catheter is removed and the resulting ...

COMPOSITION AND METHODS FOR ANTIMICROBIAL ARTICLES

A biocompatible controlled release form of complexed iodine is achieved by a complexation of polyvinyl alcohol based foam and characterized by a residual starch component to optimize iodine release profiles. The resulting iodine complexed polyvinyl alcohol foam may be utilized locally as an antimicrobial agent that releases controlled amounts of iodine sufficient to kill microbes for extended durations without excessive bulk and rigidity. 128-. (canceled)29. A method for treating a wound of a patient in need thereof , said method comprising:{'sup': '3', '(a) providing a polyvinyl alcohol (PVA) foam article comprised of PVA foam, which has a density of at least 0.074 g/cmbefore complexing with iodine, and iodine complexed at least in part to the PVA foam; and'} (i) between 50 ppm and 175 ppm at 3 hours,', '(ii) between 100 ppm and 300 ppm at 6 hours, and', '(iii) between 180 ppm and 400 ppm at 12 hours., '(b) applying the PVA foam article to a wound bed of the patient, wherein the PVA foam article exhibits controlled in vitro cumulative release of iodine in distilled water at 37 degrees Celsius at or near sink conditions of30. The method according to claim 29 , wherein the PVA foam article releases iodine continuously for at least 24 hours.31. The method according to claim 29 , wherein the PVA foam article has a thickness of from 2 millimeters to 6 millimeters.32. The method according to claim 29 , wherein the PVA foam article is packaged before application with a moisture content of at least 40% (w/w).33. The method according to claim 29 , wherein the PVA foam article further comprises a lipid-based semisolid added to the PVA foam article prior to packaging or at the time of application to the patient.34. The method according to further comprising using negative pressure wound therapy in combination with the PVA foam article.35. The method according to claim 29 , wherein the PVA foam article is a sponge for treatment of an otitis condition.36. A method for treating ...

Perfusive Organ Hemostasis

Disclosed are compositions, methods and kits to control bleeding through the use of an internal occluder based on polymeric solutions, including use of reverse thermosensitive polymers in nephron-sparing surgeries, which produces a completely bloodless surgical field, allowing speedy resection. In certain embodiments, after a certain amount of time, the flow gradually resumes, with no apparent adverse consequences to the kidney. In certain embodiments, return of blood flow may be accelerated by cooling the kidney. The compositions, methods and kits for perfusive organ hemostasis can also be used to simplify or to enable other organ surgeries or interventional procedures, including liver surgery, prostate surgery, brain surgery, surgery of the uterus, spleen surgery and any surgery on any highly vascularized organs. 1. A method of perfusive organ hemostasis in partial nephrectomy in a subject , comprising the step of introducing into an arterial vessel in fluid communication with a kidney a volume of a composition , wherein said volume is sufficient to perfuse substantially said kidney; and said composition: (a) comprises at least one optionally purified reverse thermosensitive polymer selected from the group consisting of the group consisting of poloxamer 407 , poloxamer 288 , poloxamer 188 , poloxamer 338 , poloxamer 118 , Tetronic® 1107 and Tetronic® 1307; and (b) forms a transient gel in said kidney.2. The method of claim 1 , wherein the volume of said composition is about 1-25 mL.3. The method of claim 1 , wherein said composition is introduced over about 1-30 seconds.4. The method of claim 1 , wherein said composition is a gel at mammalian physiological temperature.5. (canceled)6. The method of claim 1 , wherein said composition comprises about 5% to about 35% of said reverse thermosensitive polymer.7. (canceled)8. The method of claim 1 , wherein said at least one optionally purified reverse thermosensitive polymer has a polydispersity index from about 1.5 to ...

METHOD AND APPARATUS TO CONTROL THE HETEROGENEOUS FLOW OF BONE CEMENT AND IMPROVE OSSEOINTEGRATION OF CEMENTED IMPLANT

The present invention provides processes for combined applications of making grooves on an implant surface, applying MgO nanoparticles with PMMA cement, restricting the cement movement by PCL nanofiber and tethering biomolecules with PCL nanofiber to enhance mechanical stability and osseointegration of PMMA cement with bone. This is achieved through enhanced osteoconductive properties, roughness, and less viable fracture originating sites at the bone-cement interface. Such combined applications of nanoparticle and nanofiber on the mechanical stability and osseointegration of cemented implant is heretofore unknown, but as provided by the present invention can solve the debonding problem of cemented implant from bone. 1. A process providing a method to enhance mechanical stability and osseointegration of PolyMethylMethAcrylate (PMMA) cement with bone in surgeries using a metallic implant , comprising:amending surface areas of said implant using at least one of grooves or ion deposition;mixing nanoparticles as additives with PMMA cement;immobilizing osteoconductive nanomaterials with electrospun nanofibers (ENF), andconstruction of a membrane using said ENF said membrane exhibiting adequate stiffness to control the movement of said cement into said bone,wherein said nanofiber membrane is inserted into a formed cavity in said bone, said PMMA cement is deposited into said nanofiber membrane, and said implant is inserted into said formed cavity.2. The process of claim 1 , wherein microgroves on said implant are coupled with growth factors immobilized collagen-poly-ε-caprolactone nanofiber matrix (CG-PCL NFM).3. The process of claim 1 , wherein fibronectin (FN) and magnesium oxide nanoparticles (MgO NPs) immobilized CG-PCL NFM coating are coupled on said implant.4. The process of claim 1 , further comprising immobilizing cell adhesion matrix protein (collagen claim 1 , fibronectin) and bone growth molecules (rhBMP claim 1 , TGF-β) using said ENF membrane to increase ...

Polymeric composite materials with antimicrobial and biodegradable properties and uses thereof

A composite material for the production of a medical device having an antiseptic action includes a matrix of alginate in which the complex of iodopovidone is dispersed. The composite material is used particularly for the production of films, micro-capsules, and suture threads with iodine controlled release.

INTRAOPERATIVE USES OF SETTABLE SURGICAL COMPOSITIONS

Provided herein are settable surgical compositions and methods for their intraoperative use. 1. A method for spinal fusion , the method comprising intraoperatively mixing two or more individual reactive putties to form an HPC , optionally dividing the HPC into two or more additional portions , and inserting a first portion of the HPC into an intervertebral space to form a spacer or cage.2. The method of claim 1 , further comprising introducing one or more of an autograft material claim 1 , an allograft material claim 1 , or a bone substitute material into one or more holes drilled into the HPC spacer or cage.3. The method of claim 1 , further comprising applying a second portion of the HPC to two or more spinal pedicles adjacent to the HPC spacer or cage to form two or more HPC anchor points on the pedicles and either stretching a further additional portion of the HPC between the anchor points or positioning a rod between the anchor points and pressing the rod into the anchor points claim 1 , thereby connecting the anchor points.4. A method for stabilizing surgical hardware claim 1 , the method comprising intraoperatively mixing two or more individual reactive putties to form an HPC optionally dividing the HPC into two or more additional portions claim 1 , and applying a first portion of the HPC between the surface of a bone and the joint hardware claim 1 , applying a second portion of the HPC across the surface of the joint hardware after it has been affixed to the bone claim 1 , or applying a first portion of the HPC between the surface of a bone and the joint hardware and applying a second portion of the HPC across the surface of the joint hardware after it has been affixed to the bone.5. A method for stabilizing a surgical screw claim 1 , the method comprising intraoperatively mixing two or more individual reactive putties to form an HPC claim 1 , filling a drilled or tapped hole with a portion of the HPC claim 1 , and inserting the screw into the HPC before it ...

Hemostatic Composition And Preparation Method Therefor

Provided is a hemostatic composition comprising trypsin and zeolite, wherein pore channels of the zeolite are micropores, the zeolite contains divalent metal cations, and the mass ratio of the trypsin to the zeolite is 1:200-4:10. In the present invention, the trypsin specifically binds to the zeolite, allowing the trypsin to maintain a certain conformation on the surface of the zeolite and to obtain a higher procoagulant activity, thereby obtaining a hemostatic composition with an excellent blood coagulation effect. The hemostatic composition of the present invention has the advantages of a simple preparation method, low cost and convenient use, and can be widely used in hemostasis during trauma and operations, especially in emergent hemostasis in hemophilia patients.

FORMED SHEET PRODUCT AND HEMOSTATIC MATERIAL

A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer, and a laminated formed sheet product comprising a first polymer composition layer composed of fibrinogen and a water-soluble polymer and a second polymer composition layer composed of thrombin and an aliphatic polyester are provided. These formed products are applied onto a wound site and function as a hemostatic material. 1. A formed sheet product of a polymer composition comprising at least one protein selected from the group consisting of fibrinogen and thrombin and at least one polymer selected from the group consisting of an aliphatic polyester and a water soluble polymer , wherein at least one part of said at least one protein is incorporated into and is not covalently bonded to said at least one polymer , andwherein the formed sheet product is manufactured from a suspension composed of a solution of the polymer and particles of the protein.2. The formed sheet product according to claim 1 , wherein the at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer is selected from the group consisting of a cellulose derivative claim 1 , a polymer having an N-vinyl cyclic lactam unit claim 1 , polyethylene oxide claim 1 , polyvinyl alcohol claim 1 , hyaluronic acid claim 1 , dextran claim 1 , pullulan claim 1 , starch claim 1 , and a mixture thereof.3. The formed sheet product according to claim 1 , wherein the at least one polymer selected from the group consisting of an aliphatic polyester and a water-soluble polymer is selected from the group consisting of hydroxypropyl cellulose claim 1 , methyl cellulose claim 1 , hydroxyethyl cellulose claim 1 , hydroxypropylmethyl cellulose claim 1 , sodium carboxymethyl cellulose claim 1 , and a mixture thereof.4. The ...

BIORESORBABLE CERAMIC COMPOSITION FOR FORMING A THREE DIMENSIONAL SCAFFOLD

The present disclosure is directed to a bioresorbable ceramic composition having a plurality of biocompatible ceramic granules, each of the granules having a coating of a plurality of calcium containing particles, where at least a portion of the particles are bound to at least a portion of an outer surface of each of the granules, and further where the composition is flowable in a dry state. The present disclosure is also directed to a three dimensional scaffold for bone repair that includes the bioresorbable composition, which upon implantation to a locus of repair defines an interconnected pore network between outer walls of the coated granules of the composition. Finally, the present disclosure is directed to methods of forming both the bioresorbable ceramic composition and the three-dimensional ceramic scaffold. 111-. (canceled)12. A process for manufacturing a biocompatible ceramic composition comprising:mixing a plurality of calcium containing particles and plurality of biocompatible ceramic granules;reacting the plurality of particles and the plurality of granules with an aqueous medium;forming a calcium containing coating on at least a portion of an outer surface of each of the plurality of granules, the coating being bound to the outer surface so as to form a plurality of coated granules; and,dehydrating the coated granules.13. The process of claim 12 , wherein the step of dehydrating at least partially dehydrates the coated granules to remove excess unbound water.14. The process of claim 12 , wherein the step of dehydrating includes controlling the reactivity of at least a portion of the coating such that the reactive portion is reactive to subsequent hydraulic reactions.15. The process of claim 14 , wherein the reactive portion is calcium sulfate hemihydrate claim 14 , α-TCP claim 14 , or both.16. The process according to further comprising:forming at least an additional coating on the coated granules.17. The process according to claim 16 , wherein the ...

BONE CEMENT COMPOSITION

The purpose of the present invention is to provide a bone cement composition which can have desired biological activity performance and desired radiolucency while enabling the strength of a cured product thereof to be kept. A titanium oxide coating is formed on radiolucent particles to thereby produce composite particles, and the composite particles are added to a bone cement composition. The bone cement composition thus produced can be used suitably for the filling of a bone defect portion and the fixation of an artificial joint and in percutaneous vertebroplasty. The shape of each of the radiolucent particles is preferably granular, and the titanium oxide is preferably of a rutile type. 1. A bone cement composition comprising:(a) a composite particle comprising a particle having radiopacity and a titanium dioxide coating with which the particle having radiopacity is coated, and(b) a base material formation component comprising a methacrylate polymer.2. The bone cement composition according to claim 1 , wherein the particle having radiopacity has a granular shape.3. The bone cement composition according to claim 1 , wherein the composite particle has a median diameter of 0.2 to 7 μm.4. The bone cement composition according to claim 1 , wherein the composite particle has a BET specific surface area of 1 to 30 m/g.5. The bone cement composition according to claim 1 , wherein the titanium dioxide coating comprises rutile titanium dioxide.6. The bone cement composition according to claim 1 , wherein the composite particle further comprises a silica coating.7. The bone cement composition according to claim 1 , wherein the particle having radiopacity is made of barium sulfate or zirconium dioxide.8. The bone cement composition according to claim 1 , wherein the titanium dioxide coating comprises 1 to 30% by weight of the composite particle.9. The bone cement composition according to claim 1 , wherein the titanium dioxide coating comprises 2 to 20% by weight of the ...

Adhesive Containing Microparticles

Methods for forming and incorporating microparticles containing one or more active agents into adhesives are described. The methods involve spray drying a liquid of the one or more active agents and obtaining the active agent in a particulate form. The dry powder is then blended or otherwise incorporated with the adhesive of interest. Also described are various medical products utilizing the adhesive and one or more active agents in microparticle form, and related methods of use. 1. An adhesive composition comprising:an adhesive; andmicroparticles dispersed in the adhesive, the microparticles including a matrix material and at least one active agent.2. The adhesive of wherein the adhesive is selected from the group consisting of acrylic adhesives claim 1 , rubber adhesives claim 1 , silicone adhesives claim 1 , polyurethane adhesives claim 1 , and combinations thereof.3. The adhesive of wherein the adhesive is one of a solvent based adhesive and a hot melt adhesive.4. The adhesive of wherein the microparticles have an average span of from about 0.1 microns to about 500 microns.5. The adhesive of wherein the microparticles have an average span of from about 1 micron to about 200 microns.6. The adhesive of wherein the microparticles have an average span of from about 5 microns to about 100 microns.7. The adhesive of wherein the microparticles have an average span of from about 5 microns to about 50 microns.8. The adhesive of wherein the active agent is selected from the group consisting of pain reducing agents claim 1 , analgesics and anti-inflammatory agents claim 1 , corticosteriods claim 1 , antibiotics claim 1 , antimicrobial agents claim 1 , antifungal agents claim 1 , debriding agents claim 1 , antihistamines claim 1 , antiepileptics claim 1 , coronary vasodilators claim 1 , dermatologicals claim 1 , ancillary drugs claim 1 , and combinations thereof.9. The adhesive of wherein the active agent is a pain reducing agent.10. The adhesive of wherein the pain ...

THREE-DIMENSIONAL STRUCTURE PRODUCED FROM A MATERIAL CONTAINING POLYHYDROXYALKANOATE, KIT FOR PREPARATION OF BONE FILLER, AND INTRAMEDULLARY ROD

Provided is a material for preventing bone cement from leaking out from bone during packing of the bone cement into a bone fracture site. The bone cement can be prevented from leaking out from the bone by employing a three-dimensional structure produced from a material containing a polyhydroxyalkanoate, when packing the bone cement into the bone fracture site. 110-. (canceled)11. A three-dimensional structure produced from material containing a polyhydroxyalkanoate , and adapted for preventing leakage of bone cement when the bone cement is injected into a bone fracture site.12. The three-dimensional structure according to claim 11 , wherein the polyhydroxyalkanoate is a copolymer of at least two monomers selected from 3-hydroxybutyric acid claim 11 , 3-hydroxyvaleric acid claim 11 , and 4-hydroxybutyric acid.1311. The three-dimensional structure according to claim claim 11 , wherein the three-dimensional structure is obtained by depositing fibers measuring -100 μm in diameter produced from the material containing the polyhydroxyalkanoate.14. The three-dimensional structure according to claim 12 , wherein the three-dimensional structure is obtained by depositing fibers measuring 1-100 μm in diameter produced from the material containing the polyhydroxyalkanoate.15. The three-dimensional structure according to claim 11 , wherein the three-dimensional structure extends by 200% or more.16. The three-dimensional structure according to claim 12 , wherein the three-dimensional structure extends by 200% or more.17. The three-dimensional structure according to claim 13 , wherein the three-dimensional structure extends by 200% or more.18. The three-dimensional structure according to claim 14 , wherein the three-dimensional structure extends by 200% or more.19. A kit for preparation of a bone filler claim 11 , including the three-dimensional structure according to claim 11 , and a bone cement.20. A kit for preparation of a bone filler claim 11 , including the three-dimensional ...

SURGICAL ADHESIVE ABLE TO GLUE IN WET CONDITIONS

Compositions and methods for sealing tissue of a patient in a wet environment are disclosed. 148.-. (canceled)49. A system comprising:a multi-chamber syringe assembly comprising:a first syringe;a second syringe;a syringe housing having two first orifices at a first end and two second orifices at a second end, the syringe housing holding both the first syringe and the second syringe in parallel so that outlets of both the first syringe and the second syringe extend through the first orifices of the first end of the syringe housing and a first plunger of the first syringe and a second plunger of the second syringe extend through the second orifices of the syringe housing;a syringe clip coupled to the first plunger of the first syringe and the second plunger of the second syringe;a transfer port closure adapter having two first inlets at a third end and one second inlet at a fourth end, the third end of the transfer port closure adapter configured to be attached to the first end of the syringe housing so that the outlets of both the first syringe and the second syringe are adapted to the two first inlets of the transfer port closure adapter; anda third syringe with its outlet adapted to the second inlet of the transfer port closure adapter;a first aqueous solution having a pH of about 1 to about 5.5 in the first syringe;a second aqueous solution having a pH of about 6 to about 11 in the second syringe;a dry powder composition comprising a first component having a polymer core substituted with at least two sulfhydryl groups and a second component having a polymer core substituted with at least two sulfhydryl-reactive groups in the third syringe.501. The system of claim , wherein the syringe clip is uncoupable from either the first plunger or the second plunger.511. The system of claim , wherein the transfer port closure adapter allows contents of the first syringe , the second syringe and the third syringe to be selectively mixed.521. The system of claim , wherein the ...

RADIOACTIVE BONE CEMENT

A target tissue can be treated with a radioisotope. Some methods for treating a target tissue with a radioisotope include determining a distance between a target tissue and a surface of a matrix material to be positioned adjacent the target tissue and, based on the determined distance, determining an activity to be mixed with the matrix material to obtain a desired activity concentration. Some methods further include mixing the radioisotope with the matrix material. In some embodiments, the matrix material comprises bone cement, and the target tissue is a tumor in a bone. The radioisotope may be a beta-emitting radioisotope mixed in the cement at a concentration to form a radioactive cement. 1. A method of placing a mixture for treating a target tissue in a vertebra , the method comprising:based on (a) an activity concentration of a radioisotope in the mixture, the mixture resulting from combining a matrix material and the radioisotope, and (b) a dose of radiation to be delivered to the target tissue by the radioisotope, determining a distance between the target tissue and a surface of the mixture;placing the mixture in the vertebra, wherein the mixture is configured such that, when the mixture is placed in the vertebra, and when a closest surface of the mixture is at the determined distance away from the target tissue, the mixture delivers substantially the dose to the target tissue independently of a total volume of the mixture placed in the vertebra.2. The method of claim 1 , wherein the mixture is configured such that claim 1 , when the mixture is placed in the vertebra claim 1 , only emissions from the radioisotope within about 2.5 mm of the closest surface reach the target tissue.3. The method of claim 1 , wherein the mixture is configured such that claim 1 , when the mixture is placed in the vertebra claim 1 , only emissions from the radioisotope within about 5 mm of the closest surface of the mixture reach the target tissue.4. The method of claim 1 , further ...

BONE TREATMENT SYSTEMS AND METHODS

The present disclosure relates to bone cement formulations that have an extended working time for use in vertebroplasty procedures and other osteoplasty procedures together with cement injectors that include energy delivery systems for on-demand control of cement viscosity and flow parameters. The bone cement formulations may include a liquid component having at least one monomer and a non-liquid component including polymer particles and benzoyl peroxide (BPO). The non-liquid component may be further configured to allow controlled exposure of the BPO to the liquid monomer so as to enable control of the viscosity of the bone cement composition. 1. A bone cement composition configured to provide a controlled viscosity , comprising:a liquid component comprising a monomer; anda non-liquid component comprising first polymer beads having a first average cross-sectional dimension and comprising a radical initiator at a first amount, and second polymer beads having a second average cross-sectional dimension greater than the first average cross-sectional dimension and comprising the radical initiator at a second amount lower than the first amount.2. The bone cement composition of claim 1 , wherein the initiator is dispersed throughout each of the first polymer beads and the second polymer beads.3. The bone cement composition of claim 1 , wherein the first average cross-sectional dimension is less than 100 microns claim 1 , and the second average cross-sectional dimension is greater than 100 microns.4. The bone cement composition of claim 1 , wherein the first polymer beads and the second polymer beads comprise polymethyl methacrylate polymer (PMMA).5. The bone cement composition of claim 4 , wherein the non-liquid component comprises less than 75 wt % PMMA on the basis of a total weight of the non-liquid component.6. The bone cement composition of claim 1 , wherein the radical initiator comprises benzoyl peroxide (BPO).7. The bone cement composition of claim 6 , wherein the ...

BIOMATERIAL COMPOSITIONS

Biomaterial compositions comprising organosilicon monomers (such as silorane monomers) and chemical curing systems or dual chemical/light curing systems, in conjunction with optional tetraoxaspiro[5.5]undecanes (“TOSUs”) and/or fillers. 1. A biomaterial composition comprising:a polymerizable silorane monomer, anda curing system selected from the group consisting of a chemical curing system and a dual chemical/light curing systemwherein said silorane monomer is selected from the group consisting of 2,4,6,8-tetramethyl-2,4,6,8-tetrakis-[2-(7-oxabicyclo[4.1.0]hept-3-yl)ethyl]-1,3,5,7-tetraoxa-2,4,6,8-tetrasilacyclooxtane (CYGEP) and methylbis[2-(7-oxabicyclo[4.1.0]hept-3-yl)ethyl]phenylsilane (PHEPSI), and mixtures thereof, andwherein said curing system comprises an acid selected from the group consisting of a Bronsted acid, Lewis acid, and a superacid, and mixtures thereof.2. The biomaterial composition of wherein said acid is a Lewis acid.3. The biomaterial composition of wherein said an acid is selected from the group consisting of acetic acid claim 1 , phosphoric acid claim 1 , sulfuric acid claim 1 , hydrobromic acid claim 1 , hydroiodic acid claim 1 , trichloroacetic acid claim 1 , trifluoroacetic acid claim 1 , p-toluenesulfonic acid claim 1 , boron trifluoride claim 1 , aluminium chloride claim 1 , tin (IV) chloride claim 1 , titanium chloride claim 1 , pentafluoroproprionic acid claim 1 , triflic acid claim 1 , hexafluorophosphoric acid claim 1 , ethyl triflate claim 1 , and mixtures thereof.4. The biomaterial composition of wherein said curing system further comprises a photoacid.5. The biomaterial composition of wherein said photoacid is a phenyliodonium compound.6. The biomaterial composition of wherein said photoacid is selected from the group consisting of (4-n-octyloxyphenyl)phenyliodonium hexafluoroantimonate claim 5 , [4-(2-hydroxy-tetradecyloxyphenyl)]phenyliodonium hexafluoroantimonate claim 5 , [4-1-methylethyl)-phenyl](4-methylphenyl)iodonium ...

Bone graft substitute composition

A composition includes calcium sulfate hemihydrate, stearic acid, an accelerant, and a mixing solution. The composition can be injected, e.g., through a needle, and is capable of setting, e.g., in vivo, in a relatively short period of time to a relatively high hardness.